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General Introduction 
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GENERAL INTRODUCTION 
The study of the phamlacodynamicg of antimicrobial agents has been a rapidly developing 
line of research in recent years. Regarding this line of research it is important to appreciate 
the difference between the pharmacokinetics and the phannacodynamics of 
phamlaceutical agents. Pharmacokinetics describes the processes that take place in a 
human or animal body with a drug after a drug has been administered; it describes the 
concentration profile of the drugs in serum, in tissues, other body fluids and at the site of 
infection in relation to the dosing regimen used. Pharmacodynamics takes the 
concentration profiles of the drugs in body fluids, tissues and at the site of the infections 
into account and in the case of antimicrobial agents describes their effect on the infection 
or the bacterial population over time. Furthemlore, it also describes other pharmacologic 
effects of the drugs, including their toxic effects on host cells and tissues (Fig. I). 
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Figure 1. Diagram showing the interlinked domains of the study of pharmacokinetics and that of 
phamlacodynamics of antimicrobial agents (adapted from \V.A.Craig (4». 
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The decision which antimicrobial agent is the best choice for the treatment of an infection 
is normally based on knowledge of (a) the epidemiology of the infection and the causative 
micro-organisms involved, and (b) the susceptibility of these organisms to the 
antimicrobial agents available. Before the results of the cultures have yielded the causative 
organism and its susceptibility to various antibiotics a choice can be made empirically. 
The susceptibility pattems may result in a change to a more specific choice of antibiotic. 
The susceptibility of an antimicrobial agent is usually expressed as the minimal inhibitory 
concentration (MIC), which is the lowest concentration of the antibiotic that is needed to 
cause a visible bacterial growth inhibition in an in vitro test system. The MIC however, 
has two disadvantages: (a) the time of exposure of the micro-organism to the agent is 
fixed, disregarding existing differences in the bacterial killing kinetics of the various 
classes of antimicrobial agents and (b) the antibiotic concentration is also fixed during the 
time of exposure which sharply contrasts with the constantly changing concentration of 
antibiotics over time in vivo. 
Killing kinetics involve the study of the rate of killing induced by a specific antibiotic over 
time. For instance, an antibiotic may rapidly kill the micro-organisms and the rate of 
killing may be dependent of the drug concentration with respect to aminoglycosides. In 
contrast, bacterial killing occurs much more slowly with the p-Iactam antibiotics during 
the complete exposure time of the micro-organisms to the drug. The killing kinetics are 
usually studied in so-called time-kill experiments, where a bacterial culture is exposed to 
an antibiotic over 24 hours. Samples are taken at fixed time points to determine the exact 
bacterial count (expressed as Colony Forming Units (CFU)/ml), resulting in a curve which 
shows the bacterial killing over time (Fig. 2). In this way one can easily determine if and 
when a given drug kills a given micro-organism during the exposure time to the antibiotic. 
The second disadvantage of the MIC is that only static concentrations are used for its 
determination, while in vivo concentrations of drugs decline over time. To overcome this 
problem methods have been sought to study the effect of antibiotics all a bacterial 
infection or culuue during declining concentrations. 
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Figure 2. An example ora killing curve of P. aeruginosa at different tobramycin concentrations. 
For this purpose, animal models of infection are frequently used. Alternatively, the effects 
of a changing antibiotic concentrations on a bacterial culture can be investigated in in vitro 
pharmacokinetic models. These models were developed to mimic the pharmacokinetic 
profile of a dmg in serum, other body fluids or infection sites. The fust phannacokillctic 
model was described by Sanfilippo and Morvillo (I I). They used a dilution model (Fig. 
3), in which the declining drug profile was simulated by adding fresh medium to the 
culture reservoir. This results in an increasing culture volume during the experiment and 
consequently in an artificial decrease (dilution) in the density of the test strain as well. 
Other studies keep the culture volume constant by adding fresh medium and discarding 
spent medium with the same flow rate (1,10). However, in these models the density of the 
test organisms are also artificial lowered during the experiment. This problem is very 
important if dmgs with short half-lives arc tested since this results in a much faster 
dilution from both the dntg and the density ofthe micro·organisms. Shah (I 2) was the first 
one who tried to overcome this problem by putting a micro-glass filter in the outflow to 
prevent bacteria from leaving the test medium. In 1981 Zinner, Husson and Klastersky 
(14) described a model that was based on artificial capillary units, a system that was later 
perfected by Blaser (2). 
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Figure 3. Principle of models based on dilution. The culture is diluted with fresh broth to obtain a 
decreasing concentration gradient of antibiotic. Left: simple dilution. Right: dilution culture is eliminated to 
retain an equal volume (V) (adapted from Mouton and den Hollander (7». 
Based on this model we developed an in vitro phannacokinetic model (Fig. 4) which was 
used for the studies described in tIlls thesis. It is a two compartment model consisting of 
one central compartment and several peripheral compartments consisting of disposable 
dialyzer units (two of which are shown Fig. 4). Antibiotic is added to the central 
compartment. This central compartment is diluted from a culture broth containing diluent 
reservoir using a peristaltic pump. Antibiotic containing broth is pumped from the central 
compartment to a waste reservoir at the same flow rate, thus keeping the central 
compartment at a constant volume. The peripheral compartments consisted of disposable 
dialyzer units with a pore diameter of2.8 nm. Up to four serially connected dialyzers were 
used to allow different strains of bacteria to be studied simultaneously. Peristaltic pumps 
(17.5 mllmin) were used to circulate the bacterial culture in each dialyzer unit, to optimize 
the diffusion of fresh broth and antibiotics over the capillaries of the dialyzer units. 
Inoculation and sampling were done through silicone injection points using sterile needles. 
Each peripheral unit contained 150 ml of bacterial culture. The fluid of the central 
compartment was pumped through the artificial dialyzer units by a peristaltic pump. A 
high flow rate (125 mllmin) was chosen to obtain a rapid eqUilibrium between the central 
and peripheral compartments. The central and peripheral compartments were placed on a 
shaking apparatus (125 rpm) to provide optimum dilution of the injected antibiotic and to 
accelerate bacterial growth in the peripheral compartments. Air was blown into the broth 
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of the central compartment through a bacterial filter (O.4Sl"m). The entire system was 
placed in an incubation room at 3rC ambient temperature. Our model was described 
previously in detail (8). 
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Figure 4. Schematic diagram of the in vitro phannacokinetic model (modified and adapted from Mouton 
and den Hollander (8». 
The model enables one to obtain changing concentrations in the dialyzer compartments 
that contain the bacteria, mimicking human phannacokinctics at the site of infection. The 
half-lives can be adjusted by changing the flow rates. An example of the simulation of 
human pharmacokinetics of ceftazidime is shown in Fig. 5. 
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Figure 5. Simulated human phammcokinetic profile of ceftazidime obtained in the in vitro model. 
AIM OF THE STUDIES 
The studies presented in tlus thesis are divided in three parts, each of which addresses a 
special objective regarding the pharmacodynamics of antimicrobial agents. 
Tlteflrst objective was the comparison of the efficacy of antibiotics observed in an in vitro 
pharmacokinetic model and in an animal model. In Chapter 2 a study is described where 
the pharmacokinetics of azithromycin and erythromycin in serum of mice suffering from a 
lethal peritoneal infection with Streptococcus pnell1noniae were simulated in the in vitro 
model. Killing experiments were performed in the in vitro model simulating the same 
dosing regimens that were used to treat the infected mice. In mice bacterial killing and 
mice survival experiments were performed. In these experiments the predictive value of 
the various phannacodynamic parameters were compared for both models. 
Tlte second objective was to study the dynamics of the Postantibiotic Effect (P AE) of 
aminoglycosides. The PAE is defined as a regrowth retardation of a bacterial population 
after a limited exposure to an antibiotic. The PAE is usually determined by exposing a 
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bacterial culture to an antibiotic for a short time (1 to 2 hours), after which the dntg is 
removed from the medium and the regrowth of the bacterial culture is followed. The 
growth rate of the antibiotic exposed culture is then compared to the growth rate of a 
control culture not exposed to the antibiotic. The difference is expressed as the PAE, 
which is according to Craig and Gudmundsson (3) defined as: PAE ~ T - C, where T is the 
time required for the CFU count of the test culture to increase 1 loglo above the count 
immediately after drug removal and C is the corresponding time for the controls. Chapter 
3 gives a brief review of the PAE of aminoglycosides to introduce the experimental 
studies on the P AE. 
One of the problems in PAE determination is the removal of the antibiotic after the 
exposure. This removal can be achieved by washing, dilution or by enzymatic inactivation 
of the antibiotic. Prior to our studies with aminoglycosides, the latter method had only 
been described for fl-Iactam antibiotics. The enzymatic method has the advantage that the 
bacterial culture is not diluted during the procedure, thus it does not influence the 
detection limit, as in the dilution method. Furthemlore washing itself can cause growth 
retardation of bacteria, which is not seen during enzymatic inactivation. In Chapter 4 a 
new enzymatic method for inactivation of gentamicin and tobramycin during PAE 
measurement is described. 
The relatively large P AE induced by aminoglycosides has been used to support 
lengthening of the dose interval in clinical practice (5, 6, 9, 13). However, as indicated 
above, the in vitro PAE is detennined after an antibiotic exposure of 1 to 2 hours only, at a 
fixed antibiotic concentration, while in the human body the dmg concentrations decline 
over time, and the exposure time is much longer. The constantly declining concentrations 
of aminoglycosides in vivo may well effect the P AE. In Chapter 5 the change of the PAE 
was measured during one dose interval of tobramycin, simulated in the in vitro 
pharmacokinetic model mimicking human pharmacokinetics. During this study it became 
apparent that the PAE might be dependent on the half-life of the antibiotic, because in 
animal models PAE values differ from those observed in vitro. In Chapter 6 the difference 
between the in vitro and the in vivo PAE for tobranlycin was further investigated by 
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simulation of the pharmacokinetics of tobramycin in mice. Furthermore, the mechanism of 
the PAE was investigated and the clinical relevance of the PAE was discussed. 
Tile third objecti~'e of this thesis was to investigate the pharmacodynamics of combination 
therapy. Although combination therapy is used to treat severe infections, there is still only 
scarce information about the pharmacodynamic base for the choice of dosing regimens or 
of a choice in combination of drugs during combination therapy. Although in routine 
laboratories several tests are available to investigate the potential effects of antibiotic 
combinations, only few studies have evaluated these tests for clinical practice. Chapter 7 
reviews laboratory tests used to investigate the interactions of antibiotic combinations. 
In Chapter 8 combination therapy of ceftazidime and tobramycin was investigated during 
different dosing regimens against a resistant Pseudomonas aeruginosa strain. The order of 
antibiotic administration during combination therapy is not standardized on the basis of 
pharmacodynamic data and, thus arbitrary choices are made mainly. \Ve investigated the 
effect of the order in which the antibiotics are given on the bacterial killing. In Chapter 9 
the same drug combination was used in fourteen different dosing regimens against four 
resistant Pseudomonas aeruginosa strains. This study was performed to determine 
phannacodynamic parameters, which may be used to predict therapeutic efficacy of 
combination therapy. Such parameters n~ay give more insight in the rationale behind the 
dosing regimens of combination therapy and can be useful in guiding further clinical 
studies. 
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ABSTRACT 
In this study we detcnllined the efficacy of various dosing regimens for erythromycin and 
azithromycin against four pneumococci with different susceptibility to penicillin in an in 
vitro pharmacokinetic model and in a mouse peritonitis model. The Mle was 0.03 mgtl, and 
the 50% effective doses (determined after one dose) of both drugs were comparable for the 
four pneumococcal strains and were in the range of 1.83-6.22 mglkg. Dosing experiments in 
mice, using regimens for azithromycin of one to eight doses/6h, showed the onc-dose 
regimen to give the best result. Of the phamlacodynamic parameters tested (the maximum 
drug concentration in senllu [C",lAX]' the time that the drug concentration in serum remained 
above the MIC [T>MIc1 and above the concentration required for maximum killing 
[T>MAXKruJ, and the area under the concentration time curve [AUCD, CMAX was the best 
predictor of outcome. The bacterial counts in mice blood or peritoneal fluid during the fIrst 
24 h after challenge were not correlated to smvival of the mice. The serum concentration 
profIles obtained in mice for the different dosing regimens were simulated in the in vitro 
phanl1acokinetic model. Here as well, the one-dose regimen of azithromycin showed the best 
result. However, the killing curves in vivo in mouse blood and peritoneal fluid and in the 
vitro pharmacokinetic model were not similar. The in vitro killing curves showed a decrease 
of2loglO within 2 h and 3 h for azithromycin and erythromycin respectively, whereas the in 
vivo killing curves showed a bacteriostatic effect for both dmgs. It is concluded that the 
results in tenus of predictive phamlacodynamic parameters are comparable for the in vitro 
and the in vivo models and that high initial concentrations of azithromycin favor a good 
outcome. 
INTRODUCTION 
Although macrolides are being used to treat moderate to severe infections, it is not well 
known how effective these dmgs are in the treatment of infections that are accompanied by a 
severe sepsis syndrome (5,9,11, 14, 15,24,26). One of the problems is that the volume of 
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distribution of these drugs is quite large, resulting in relatively low concentrations in serum 
(10, 18, 22). Thus the relationship between the concentration in senun and the MIC for the 
infecting micro-organism never attains high values and remains questionable. TIus is 
especially true for the recently clinically introduced 15-membered macrolide the azalide 
azithromycin, wluch has an even greater volume of distribution. For example, the range of 
azithromycin concentrations in tissue is 1 to 9 mg/kg, which is 10 to 100 times the 
concentration in serum (6, 7, 30). The importance of the high ratio of the concentration in 
serum to MIC has not been established for azithromycin. Since the occurrence of penicillin 
resistance in pneumococci (16), the quest for knowledge about the efficacy of alternative 
drugs in the treatment of pneumococcal disease is warranted. 
There are several ways to shed light on tlus issue by using a mouse sepsis model, the 
survival of mice or the bacterial counts can be determined, and by measuring the concen-
trations of the macrolides in the different body compartments, the relationship between drug 
concentration and efficacy can be determined. Although this latter approach has been used in 
several animal models, in none of these models a severe sepsis syndrome was present (I, 3, 
23, 29). Another approach would be to simulate the phannacokinetics of the macrolides in 
an in vitro pharmacodynamic model and detennine the antimicrobial efficacy of macrolides 
given in several dosing regimens. By combining the results of in vitro and in vivo efficacy 
experiments, more detailed insight into the phannacodynamic principles of macrolides can 
probably be gained. Such a combined approach would also be of value when defining 
breakpoints for in vitro susceptibility testing in routine laboratory tests. However, the usual 
method of relating MICs directly to concentrations in senun can obviously be applied to 
macrolide drugs only within certain limits. 
The purpose of the present study was twofold. The first goal was to investigate the efficacy 
of one of the recently clincally introduced macrolides, azithromycin, in the treatment of a 
severe sepsis syndrome and to determine which pharmacokinctic and phannacodynamic 
parameters are the best predictors of efficacy. 
TIle second objective of the study was to compare data derived from an animal infection 
model with those detennined in an in vitro phannacodynamic model. There is, as far as we 
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know, only one previous study comparing the results of an in vitro model with those of an 
animal model. (2). However, in that study, efficacy, as measured by killing effect, was 
comparable in both models, but macrolides were not used. 
MATERIALS AND METHODS 
Strains, antibiotics, and media. The strains used for the experiments were four clinical 
isolates of Streptococcus pneumoniae with different susceptibilities to penicillin. The 
serotypes were determined at The Streptococcus Department, Statens Serum Institut 
(Copenhagen, Denmark), by using anti-capsular polysaccharide antibodies (19). 
Erythromycin (E 6376; Sigma Chemical Company, St. Louis. Mo.) and azithromycin 
(azithromycin dihydrate; Pfizer Pharmaceuticals, Ringasskiddy, Ireland) were used and 
dissolved according to the manufacturers' instructions. All in vitro experiments were 
performed in Mueller Hinton broth (MHB; Difco, Amsterdam, The Netherlands). Todd-
Hewitt broth (Difeo) was used to culture pneumococci prior to the time-kill experiments, 
and beef broth (Statens Serum Institut) was used as the medium for pneumococcal cultures 
prior to mouse experiments. All experimental samples were plated on 5% blood agar 
plates (Sanofi Pasteur, [Maassluis, The Netherlands] and Statens Serum Institu!). 
MICs, generation time, and conventional time-kill curves, MICs for erythromycin and 
azithromycin were detennined by using a standard agar dilution method (21), a 
macrodilution method (21), and the gradient disk diffusion method (E test; AB Biodisk, 
SoIna, Sweden). The generation times of all strains was determined during conventional 
logarithmic growth in tubes of MHB. Conventional time-kill experiments were performed 
with erythromycin and azithromycin at concentrations of 0, 0.25, 0.5,1, 2, 4, 8,16,32,64, 
and 128 times the MIC in shaking tubes containing 10 ml MHB. All time-kill curves were 
perfonned in duplicate. For each experiment, a fresh culture was made in 30 ml Todd-
Hewitt broth inoculated with 5 x 10' CFU of a standardized pneumococcal batch stored at 
-80'C. After 12 h incubation at 37'C, these cultures were diluted in prewarmed MHB and 
shaken for 1.5h at 37'C, resulting in a logarithmic phase culture of 5 x 10' CFU/ml. 
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Samples were then diluted with prewarmed MHB containing twice the final antibiotic 
concentration. Samples were subsequently taken at t = 0, t, 2, 4, and 6 h and the numbers 
of CFU per milliliter were determined after making appropriate lO-fold dilutions in cold 
phosphate- buffered saline (PBS, pH~7.4). From each dilution, 0.1 ml was plated on a 5% 
blood agar plate and incubated for 48 hours at 37'C (limit of detection, 10 CFU/ml). 
Mouse peritonitis model. All animal experiments were approved by the animal ethical 
commitee. The model was previously described in detail (17). Briefly, outbred female 
ssc:CFt mice (age, approximately 8 weeks, weight, 30 ± 2g) were used throughout the 
study. The mice were kept at five per cage and had free access to chow and water. From 
fresh overnight cultures on 5% blood-agar plates, an inoculum was prepared immediately 
before inoculation by suspending colonies in sterile beef broth medium and diluting it to a 
suspension containing approximately 2 x 10' CFU/ml. Mucin (M-2378; Sigma Chemical 
Company) was used as an adjuvant for inoculation of the mice. Inuuediately before 
inoculation, the mucin solutions were diluted 1: 1 with the pneumococcal suspensions, 
yielding a final mucin concentration of 5% (wt/vol). The final number of CFU per 
milliliter in the inoculum was determined by plating on 5% blood agar. Inoculation was 
performed by intraperitoneal injection of 0.5 ml of the inoculum. Blood samples were 
obtained by cutting of the axillary artery after anaesthetizing the mice with CO,. After the 
mice were sacrificed, peritoneal washes were performed by Lp. injection of 2 ml of sterile 
saline, and after the abdomen was massaged, the peritoneum was opened for fluid 
collection (8). Blood and peritoneal fluids were immediately diluted, and duplicate 20 pi 
samples were plated in spots on 5% blood agar plates. Mice were treated by administering 
subcutaneous iqjections in the neck region. 
Determination of the ED,w The 50% effective doses (EDsos) were determined by 
administration of one-dose treatments 1 h after challenge with pneumococci. The 
determinations were done in two steps, for each dmg and strain. In the first step, 25 mice 
were treated in groups of 5 with five successive 10-fold higher doses of the antibiotics. 
The maximum dose was 100 mglkg. In the second step, 25 mice were treated in groups of 
5 with doses within the range of the EDsos estimated in the first step. A group of five 
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control mice was included in every experiment. The drugs were administered as a single 
injection of 0.5 ml subcutaneously. The mice were observed for 6 days, and mortality was 
registered. 
Table 1. In vivo and in vitro efficacies of azithromycin and erythromycin against four S. pneumol1iae 
strains. 
Strain/serotype MIC(mg/l) EDso (mg/kg)' Generation 
(95 % CI) time (min) 
inMHB in 
vitro 
Azilhromycin Erythromycin Penicillin Azithromycin Erythromycin 
68040/68 0,03 0,03 0.016 1.83 3.75 53 
(0.34·4.90) (1.27-8.28) 
964/14 0,03 0.03 0.25 3.87 3.48 44 
(1.49·4.90) (0.54·13.55) 
999/19A 0,03 0,03 0.5 6.22 4.15 31 
(2.95-12.97) (1.18-10.51) 
1064/68 0,03 0,03 0.25 4.84 2.15 31 
(4.84-4.84) (0.37-6.04) 
A ED5~ were dctennined in mice. cr, confidence interval 
Pharmacokinetics in mice. Pharmacokinetic studies of erythromycin and azithromycin 
in healthy mice were performed. For each time point, blood was collected from three mice 
for determination of the antibiotic concentration. After collection of the samples, the blood 
was centrifuged at 1,630 x g for 10 min and the serum was stored at -80°C until analysis. 
The cup plate or the disk diffusion bioassay method (4) was used to measure the 
concentrations of erythromycin and azithromycin in mouse serum. Sarcina lutea ATCC 
9341 was used for the bioassay. The lower limit of detection was 0.125 mg/!. The 
variation coefficients were below 5% for all of the bioassays used. All detenninations 
were performed in duplicate. 
Dose regimens in mice. The treatments were always initiated 1 h after challenge, a time at 
which the bacteria were known to be in the growth phase (17). The total dose of either 
erythromycin or azithromycin was 4 mglkg, given either as one dose or divided into four 
doses of I mg/kg, with a dosing interval of two semm elimination half-lives (tins) (t ~ 0 
and 80 min and t = 0 and 100 min, respectively). These regimens were chosen because of 
the difference between the tins of the two dmgs and the fact that we wanted to obtain 
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comparable regimens for the drugs. In mouse survival studies, the same dose of 4 mg/kg 
was given as one, two, four, or eight doses for azithromycin (i.e. 4, 2, I, 0.5 mg/kg, 
respectively). with dose intervals of 4, 2, and 1 times the tl/2' respectively. Erythromycin 
was dosed once or as four doses with an interval of twice the tl/2' A group of control mice 
was included in every experiment. 
In vitro model. The model used was described prcviously in detail (20). Briefly, a two-
compartment model consisting of onc central compartment and four peripheral 
compartments consisting of disposable dialyzer units (ST23; Baxter, Utrecht, The 
Netherlands) was used to expose the bacteria in the peripheral compartments to declining 
antibiotic concentrations that vary according to mouse pharmacokinetics. Hundred and 
fifty milliliters of a logaritlunic phase culture containing 5 x 10' CFU/1ll1 (prepared freshly 
as described above) was injected into the peripheral compartments of the in vitro model. 
Samples were taken at the intervals indicated in Results for determination of the CFU and 
antibiotic concentration. The peak concentrations (C},tAx), time to the C"tAX (T"tAx), and the 
tl/2 of the antibiotics in the model were adjusted to those found in the mouse model. 
Antibiotic treatment was started at t = 0 h with an infusor (Braun AG, Melsungen, 
Germany). 
Dose regimens in vitro. The erythromycin and azithromycin regimens used for the mice 
were simulated in the in vitro model (see above). Samples were taken every hour starting 
at t = 0 h. At 10 and 20 min after the CMAX was reached, additional samples were taken for 
antibiotic concentration detennination. Antibiotic concentrations were detennined using 
the cub agar diffusion method as described above. These concentrations were used to 
check the CMAX and tl/2' All regimens were perfonned in quadruplicate. 
Analysis and statistical methods. The logit transformation was used to calculate the EDso 
(27). The tll2s of erythromycin and azithromycin in mice and in the vitro model were 
estimated from the expression, -log 2/P, where P is the slope of the serum elimination 
regression linc (time versus the log of the concentration in serum). From the conventional 
time-kill curves, the minimum concentration of the drugs given the maximal achievable 
killing of the pneumococcus were defined. The CbtAXl the time to the CbtAXl the TbtAXl and 
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the time that the drug concentration in serum remained above the MIC (T.M1C) and above 
the concentration required for maximum killing (T>MAX.KllJ were estimated from the serum 
elimination regression line. A simulation of the antibiotic concentration profile during all 
experiments was done by using the formula of an open-compartment model after 
extravascular administration (25). The area under the concentration-time curve (AVe), 
T>MIC and T>MAXKILL (Le. time above a concentration equivalent to four times the MIC) were 
calculated using these simulated curves. 
The Hill equation with variable slope was used to describe the dose-response curves of the 
conventional time-kill experiments. Statistical analysis of the bacterial killing curves (Le. 
the difference between 10giO CFU per milliliter at t ~ 0 hand t ~ 6 h), both for the in vitro 
model and for the cOllventional killing curves, was done by two-way analyses of variance 
and Tukey's test for multiple comparison of significance (13). 
The method of Kaplan-Meier was used for evalution of the survival data using product 
limit survival estimates. The log rank test was used to determine significant trends in the 
curves (12). 
To determine which pharmacokinetic parameters arc predictive of efficacy, multivariance 
analyses were perfonned using forward and backward elimination procedures (27). The 
following parameters were included in the model: Cr,lAx. TMAx, TMAx.K,LL, and AVC. A p-
value'; 0.05 (two-tailed) was considered significant. 
RESULTS 
MICs and EDsos. The capsular serotypes and in vitro generation times of the four c1incal 
isolates of S. pneumonia tested are given in Table I, as are the MICs and the EDsos of 
azithromycin and erythromycin. The MICs were identical for all four strains and with all 
of the three methods used (data not shown), and the ED"s for mice were also highly 
comparable. 
Conventional time kill expel'iments. Results of time-kill experiments with strain 1064 
exposed to azithromycin and erythromycin in vitro are given in Fig. 1. The change in loglo 
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CFU per milliliter was plotted against the concentrations as mUltiples of the MlC and then 
fitted to the Hill equation. The curves fitted to the counts obtained after 4 h of exposure show 
that maximum killing was reached at 4 times the MIC. In contrast, if 1 h exposure values are 
used, maximum killing for azithromycin was reached only at 128 times the MIC, indicating 
that there is concentration-dependent killing if strains are only briefly exposed to the drug. 
This latter phenomenon was not observed with strain 964; (data not shown). 
Pharmacokinetics in mice and in the in vih'o model. The T 1>1AX , CMAX , and tl12 (mean ± 
SD) determined with mice for azithromycin and erythromycin were 10-20 min, 0.8-1.0 
mg/I, and 43 ± 8 min and 51 ± 10 min, respectively. On the basis of these observations, the 
phannacokinetic profile of the free fractions of these dmgs were simulated in the in vitro 
model. The C'IAX in the model was adjusted to 0.8 mg/I for both drugs taking into account 
approximately 20% protein binding for erythromycin and <8% for azithromycin (28). There 
were no significant differences between the observed relevant phanllacokinetic parameters in 
vivo and in vitro. The actual detemlined drug concentrations during the experiments fitted 
well in the simulated drug-time profile for all regimens (data not shown). 
Efficacy studies. (i) CFU counts, In mice, the efficacy of a 4 mg/kg dose of azithromycin 
and erythromycin, administered either in one dose or in divided doses, was determined by 
CFU counts in blood and in peritoneal fluid taken at intervals up to 6 h. The number of 
CFU in blood generally followed the same time course as that found in peritoneal fluid 
(Fig. 2). Erythromycin had only a slight bactericidal effect both in blood and in the 
peritoneum, as was true for azithromycin as well. At t = 6 h, no significant difference 
between the two dose regimens of either macrolide could be demonstrated. 
When the same dosing regimens were used in the phannacokinetic model, there was no 
apparent difference between the one-dose regimen of erythromycin and the same dose 
divided into four doses. In contrast, for azithromycin the one-dose regimen was 
significantly more efficacious than the four-dose regimen (p~0.02). This difference 
became apparent after the first hour of exposure, 
Comparison of the data for erythromycin and azithromycin showed a better killing in vitro 
for azithromycin given as one dose than by one dose of erythromycin (p~0.0 1). However, 
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no significant difference in efficacy was observed between the other azithromycin and 
erythromycin dosing regimens. Experiments with strain 964 showed similar results (data 
not shown). 
(ii) Pharmacodynamics in mice versus in vitro. The survival rate of mice observed for 6 
days after treatment with the different regimens showed that there was a difference in 
efficacy between the different dosing regimens of azithromycill (Table 2), Kaplan-Meier 
survival analysis showed that there was a trend for an increased survival when 
azithromycin is administered less frequently (p=.OO 1). In contrast, survival of mice was 
not different for erythromycin regimens (p~0.83). 
The correlation between survival of mice and the bacterial counts were studied during the 
dosing experiments. \Ve did not find any correlation between survival of mice and the 
bacterial counts either in blood or in peritoneal fluid. In one of the experiments the counts 
were measured during the treatment period (Table 2). In another of these dosing 
experiments the counts were determined in five mice from each treatment group 24 h after 
challenge. The results given as IOglO counts in blood and peritoneal fluid, as medians and 
ranges, and the 6·day survival of mice treated equally, are shown in Table 3. There was no 
significant correlation between the killing at t = 24 h and survival in mice. 
To determine which of the pharmacodynamic parameters (AVe, T>,\flCl e~tAX' or T>MAx_Kll.L) 
was most predictive for the outcomes of the different azithromycin regimens in vivo and 
in vitro, a multi variance analysis was perfonlled, despite of the few data sets. Both for 
survival and for killing in the in vitro model, the e~tAX appeared to be the most significant 
predictive parameter ([p~.OOll and R2~OA9 [p~.003], respectively). In the in vitro model 
the coefficients of detennination for the other pharmacodynamic parameters had R2 values 
of 0.10 (p~0.24), 0.35 (p~0.015), and 0040 (p~0.009), for T'MAXKILL' Ave and T'MIC' 
respectively. For the survival experiment, the p values of the survival analysis were 0.006 
and 0.072 for T>MAXKll.L' and T>M!Cl respectively. For the AVe no calculations were 
possible in vivo since we only used one dose. For erythromycin such an analysis was not 
possible due to the smaller number of dosing regimens tested. 
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Figure 1. Growth and killing of S. pneumoniae 1064 exposed to increasing concentrations of erythromycin 
(top) or azithromycin (bottom). TIle change in log CFU is the difference in CPU at t = 0 h and at 1 h (0) or 
4 h (0), respectively. The symbols indicate the observed CFU, and the curves are fits obtained by using a 
sigmoidal dose·respol1se equation with a variable slope. TIle data are means of two separate experiments. 
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Figure. 2. Killing of S. pneu1lIoniae 1064 in mice (top) and in the in vitro model (bottom), Control data on 
the growth of the strain in vitro (x) and in the blood (-X-) and peritoneum (---x---) of mice are shown in all 
oflhe graphs. TIle symbols correspond to exposure to one dose (II) or in four divided doses (0). For the in 
vivo experiments, curves indicated by solid and broken lines indicate the number of CFU in blood and the 
peritoneum, respectively. 
Table 2. Survival of mice challenged with S. pneumoniae 1064 and pneumococcal killing effects of erythromycin and azithromycin in vivo and in vitro. 
In vivo data 
No. of mice Change in log CFU at 6 h 
No. of 
dosesA 
dead / total in blood I peritoneal fluid 
(%) within (95% CI) C 
6 days 
Azithromycin 
I 37/S5 (44) 
2 29/54 (54) 
4 30/55 (55) 
S 41155 (75) 
Erythromycin 
I 24/30 (SO) 
4 24/30 (SO) 
0.5 (-0.1 to 1.0) /0.02 (-1.3 to 1.3) 
ND' 
0.5 (0.5 to 0.5) / -0.4 (-7.S to 7.0) 
ND' 
-02 (-0.5 to 0.1) / -1.2 (-4.9 to -{l.S) 
-0.9 (-1.6 to -{l2) / -1.2 (-2.2 to -{l2) 
A The total amount of each drug given in each case was 4 mg/kg. 
b Calculated from simulated curves. 
C CI, confidence interval. 
d ND, not done. 
In vitro change 
in log CFU at 6 h 
(95% CIl' 
-2.4 (-2.8 to -2.1) 
-1.6 (-2.0 to -1.3) 
-1.6 (-2.3 to -{l.9) 
-1.6 (-1.7 to-1.5) 
-1.9 (-2.2 to -1.9) 
-2.3 (-2.5 to -2.1) 
CMAX 
(mglI) 
(xMIC) 
0.8 (26) 
0.4 (13) 
0.2 (6.5) 
0.1 (3.3) 
O.S (26) 
02 (6.5) 
Pharmacokinetic parametersb 
T>Mlc(h) T>MAX.Kll.r.<4 AUCo_6 
4.2 
6.9 
7.5 
7.5 
3.2 
6.4 
x MIC) (h) (mglI.h) 
2.5 
3.6 
3.2 
o 
2.0 
3.6 
1.2 
12 
0.9 
0.6 
1.0 
1.0 
Aueo . .., 
(mglI.h) 
1.2 
1.2 
1.2 
1.2 
1.0 
1.0 
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Table 3. Bacterial counts at t = 24 h and survival of mice during one experiment using different 
azithromycin dosing regimens. 
No. of Log median Log median No. of mice 
Doses' blood CFU count peritoneal CFU count dead/total 
(range) (range) (%) within six days 
o (control) 4.23 (1.70·7.43) 6.68 (5.38·11.11) 10/10 (100) 
4.10 (3.23·6.89) 7.26 (6.99·8.95) 10125 (40) 
2 1.70 (1.70·2.35) 4.38 (1.11·5.75) 9124 (37.5) 
4 3.72 (1.88·4.94) 6.58 (2.77·7.70) 14/25 (56) 
8 3.80 (3.04·5.18) 9.88 (5.78·9.95) 16/25 (64) 
a The total amount ofazithromycin administered in each case 4 mglkg. 
DISCUSSION 
In this study, we evaluated the pharmacodynamic parameters of efficacy for macrolide 
antibiotics (azithromycin and erythromycin) in a mouse model ofa severe sepsis syndrome 
due to bacteremial pneumococcal infection and compared these with the same parameters 
in an in vitro phannacokinetic model. In both models, the azithromycin Cl\lAX was most 
predictive of success, indicating that large doses given infrequently are better than the 
same amount of the drug given in multiple doses with shorter dosing intervals. 
The results of the conventional time-kill experiments indicate that the maximum 
bactericidal effect of azithromycin is reached at four times the MIC. However, there 
appears to be a greater concentration-dependent effect during the first hour of exposure to 
azithromycin. This effect disappears after I to 4 h. One of the explanations could be that 
there is some kind of concentration-dependent uptake ofazithromycin in the cell. If this is 
the case, it could be argued that the first dose of azithromycin should be high. On the other 
hand. the maximum effect after 1 h is only 1 loglO decrease whereas a 2 ioglO decrease is 
achieved after 4 h; thus, the net initial effect of a high first dose would probably be 
marginal. 
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The killing experiments performed in the in vitro pharmacokinetic model showed a 
significantly better result when azithromycin was given as one dose than when it was 
given in a multiple·dose regimen. This benefit of one dose became apparent during the 
first hour of exposure (Fig. 2). We calculated that the C'IAX reached during the one-dose 
experiment corresponds to 16 to 32 times the MIC. Beyond I h, the kinetics of the killing 
more or less paralleled to that of the other dosing regimens, which contrasted to the 
progressive killing observed in the conventional time·kill experiments. This difference can 
be explained by the decrease in concentrations of azithromycin in the pharmacodynamic 
model, as opposed to the static concentrations in the conventional killing experiments. 
In vivo, the initial effects of azithromycin on the CPU counts in blood and the peritoneum 
were quite similar, irrespective of the dosing regimen. There was no obvious relationship 
with in vivo efficacy and the data obtained with the in vitro model. An explanation could 
be, that the pneumococcal growth rate is significantly different in the two systems. 
Comparison of bacterial killing in vitro and in the mice showed significant differences both 
during the 6 h of treatment and 24 h after challenge. The same factors as just mentioned to 
explain the in vivo results may be responsible for this. One way to obtain more comparable 
results would be to reproduce the exact in vivo growth rate of pneumococci in the in vitro 
model, for instance by adjusting the composition of the medium. Another possibility would 
be to compare killing curves obtained with the in vitro and in vivo models after correcting 
for differences in the rate of growth. In tlus case, the observed differences between in vitro 
and in vivo killing by azithromycin disappears (results not shown). Although this latter 
approach seems attractive, the results fmUld may become highly dependent on differences in 
growth rate and may poorly reflect the antimicrobial activity of the agent itself. We conclude 
that initial bacterial killing rates obtained with the two models are not directly comparable. 
The results of the mouse survival experiments showed that azithromycin administered as one 
dose significantly increased the survival rate as compared with all other regimens. 
Furthennore, trend analysis of trend showed that survival was inversely related to the 
number of divided doses given. This indicates that the C~fAX may be an important 
pharmacodynamic parameter for prediction of clinical efficacy. Other phannacodynarnic 
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parameters did not show such a consistent relationship with survival. These results are in 
agreement with those obtained from the phannacodynamic model, as regression analysis of 
the in vitro results likewise showed the C~1AX to be the single significant parameter that 
explains the efficacy of azithromycin. 
Thus, although the initial (6-h) killing rates obtained with the two models are not directly 
comparable, the final conclusion with regards to the phanllacodynamics of azithromycin are 
the same. This was also shown for another in vitro and in vivo model comparison using 
other antibiotics (2). 
The data for the two erythromycin regimens tested (Table 2) showed no significant 
difference in either the survival data or the killing data from the in vitro model. 
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INTRODUCTION 
The Postantibiotic effect (P AE) is a term that describes the period of suppression of 
growth of a bacterial population after a short exposure to an antimicrobial agent (7). The 
phenomenon of suppression of bacterial regrowth after exposure to antimicrobials was 
first described by Bigger in 1944 (4). Several years later, Parker and Marsh (46) and 
Parker and Luse (47) showed that Staphylococci shortly exposed to penicillin G (5-30 
min) and thereafter transferred to a drugMfrce medium did not inmlcdiately resume their 
nonnal growth rate but did so only I - 3 hours later. This prolonged suppressive effect of 
antimicrobials after their removal was also confinned in vivo (15, 16, 17). 
It was not until the mid 1970s that this prolonged suppression of bacterial regrowth after a 
short exposure to an antimicrobial agent was defined as the PAE. During the following 
years the possible clinical significance of PAEs became more and more apparent due to 
the work of Craig and Gudmundsson (7). In the same period the integration of 
phannacokinetic data and the effect of drugs on the targets during treatment became more 
intensively studied and came to be known as the pharmacodynamics of the drugs. From 
this new line of research several pharmacodynamic parameters became apparent, which 
gave more support for certain dosing regimens in the clinical setting. For example, the area 
under the concentration time curve (AVe), the peak concentration (CMAX)' the time above 
the MIC (T,,,[e), and the postantibiotic effect (PAE) are phannaeodynamic parameters that 
may correlate with efficacy of a given agent. Before the use of these pharmacodynamic 
parameters dosing regimens were often chosen arbitrarily and inconsistencies could be 
observed in every day clinical practice. For example, gentamicin was usually given at 6- or 
8-hourly intervals and amikacin at l2-hourIy intervals (20); both drugs are from the same 
aminoglyeoside class and have the same half-life (40). Of the pharmacodynamic 
parameters described above, the PAE seemed to one of the more important parameters to 
reveal a scientific base for the dosing frequency or administration profiles of antimicrobial 
agents, in particular aminoglycosides. Since the PAE refers to a period of prolonged 
growth suppression after the antibiotic has been removed from the medium it was used to 
support the lengthening of the dosing interval of aminoglycosides. Until then, it was 
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commonly assumed that the concentration of virtually all antimicrobial agents had to be 
above the MIC for the whole dosing interval to assure efficacy. Currently aminoglycosides 
are given once daily (41). The evolution of the aminoglycoside dosing regimens has 
primarily been based on the phannacodynamics of their efficacy as well as that of their 
toxicity. Aminoglycosides show a strong concentration dependent killing (19, 33, 52, 53, 
56), little influence of the inoculum of bacteria (11), and emergence of resistance during 
therapy is rarely seen (20). Furthermore, the once daily regimens may reduce toxicity (20), 
but the studies conceming toxicity will not be discussed here. The change to a once daily 
dosing regimen was supported not only by the fact that aminoglycosides have a large 
concentration dependent PAE, but also because they show antimicrobial activity below the 
MIC (57, 58), and are associated with a temporary adaptive resistance among the bacterial 
population surviving the initial exposure (2, 9, 10,21,22,35). 
The purpose of tItis review is to evaluate the PAE of aminoglycosides and to discuss its 
clinical relevance. ' 
METHODS USED TO DETERMINE THE rAE IN VITRO AND IN VIVO 
PAE;II vitro. The PAE is defined as a rcgro\\1h retardation after a limited exposure to an 
antibiotic. In vitro and in vivo methods for PAE detennination have been described by 
Craig and Gudmundsson (7). In vitro, the PAE is defined as PAE ~ T - C, where T is the 
time that the exposed culture needs to regrow 1 10gIO CFU/ml, and C is the corresponding 
time for the control culture not exposed to an antimicrobial agent (Fig. la). 
The PAE is detennined in vitro using a logaritluuically growing bacterial culture at a 
density of approximately 107 CFU/ml. This inoculum is exposed to an antimicrobial agent 
during 1 to 2 hours. after wltich the drug is removed from the medium, and regrowth is 
subsequently deternlined in the exposed culture and in the control culture. The critical step 
in the procedure is removal of the active drug which can be done by one of three methods, 
i.e. (a) washing the bacteria free from drug by centrifugation and resuspending in drug free 
medium, (b) dilution of the exposed culture (100- to 1000-fold) or (c) by enzymatic 
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inactivation of the drug. The first two methods have considerable drawbacks. The washing 
procedure itself may cause growth retardation and thus may influence the PAE. The 
dilution method has the disadvantage that at least 10' to 10' CFU/ml need to survive the 
initial exposure to the antibiotic in order to monitor regrowth accurately. which is 
especially a problem for antibiotics with a pronounced and rapid killing elIect (e.g. 
aminoglycosides). Enzymatic inactivation of the drug does not have these disadvantages 
but has been described for p-Iactam antibiotics only. In Chapter 4 an enzymatic 
inactivation method for aminoglycosides is described (12), which overcomes the problems 
of the first two methods. 
The most widely used and generally accepted method for PAE determination is viable 
counting (7), However, other regrowth detection systems have been described, because the 
viable counting method is laborious, and not easily automated. Furtltennore, when using 
pwlactam antibiotics and Gram negative bacteria viable counting may result in low 
CFUlml at the first time-point after removal of the drug, due to filament forming during 
antibiotic exposition. Filaments are very long chains of bacteria that can grow during the 
exposure to ~-Iactam antibiotics if the agents inhibit the final stage of division of the 
bacteria. After the removal of the drug the long filaments will start breaking up in 
individual cells resulting in a sudden rise in the bacterial count, which could even result in 
negative PAE values. Many other methods have been described for bacterial growth 
detection but all have had only limited application in P AE experiments, examples are: 
impedance measurements (I, 27), bacterial ATP (31, 44), spectrofotometry (49), electronic 
particle counting (36, 42), morphology (29, 38), and measuring CO, generation of bacteria 
(26). Most of these methods have been reviewed by Mackenzie and Gould (40). 
PAE ill vivo. The in vivo method for PAE determination differs somewhat from the in 
vitro method. In the in vivo method several infection models have been used, Le. the 
murine thigh infection (17, 28), the rabbit meningitis model (50), the rat endocarditis 
model (30), and the mouse pneumonia model (8). Of Owse methods the murine thigh 
model has been used most frequently. The PAE in vivo is expressed as: PAE = T - C - M, 
(Fig. I b) where M represents the time during which the serum concentration exceeds the 
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Figure 1. (a) An example of the detemlination of the PAE in vitro. PAE = T - C according to Craig and 
Gudmundsson (7), and (b) an example of the detemlfnation of the PAE in vivo, for example in a mouse 
thigh model with a half-life ofO.5h for the antibiotic. PAll is detennined as PAE = T - C - M, according to 
Craig and Gudmundsson (7), see text for details. 
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MIC, T is the time required for the number of CFU in the thighs of the treated mice to 
increase 1 loglo above the count at time M, and C is the time needed for the number of 
CPU in the thighs of the untreated controls to increase 1 iog lO above the viable count at 
time zero (7, 54). The important difference between the in vitro and in vivo method is that 
during in vitro the PAE detemlination regrowth is measured in antibiotic free medium, 
while in vivo the antibiotic is not removed or inactivated completely and the PAE is thus 
determined under sub-MIC conditions. (Fig. I). To overcome this problem, an extra 
control growth curve was introduced (7). A fresh inoculum of bacteria was injected into 
the contra-lateral thigh of mice given the dmg at the time the antibiotic concentration had 
dropped below the MIC. The growth curve of this latter inoculum was not significantly 
different from the bacterial growth rates found in untreated animals. 
Mechanism of the PAE. The precise mechanism of the PAE is still not completely 
known. There is consenSllS that the exact mechanism differs with the combination of 
antibiotic and organism and involves multiple mechanisms and metabolic pathways (7, 40, 
59). The PAE is thought to result from either cellular recovery after reversible, nonlethal 
damage, or from persistence of the antimicrobial agent at the target site of action. 
The mechanism by which aminoglycosides exert their action is by binding irreversibly to 
ribosomes and interfering with the protein synthesis. One of the explanations of the PAE 
of aminoglycosides is that it may represent the time needed for the bacteria to synthesize 
new ribosomes (31). Another possibility is that the free aminoglycoside remaining inside 
the bacteria after removal of the drug causes growth retardation during the regrowth phase. 
However, this latter mechanism can explain only in part the PAE induced by 
aminoglycosides, as is discussed in Chapter 6 (14). The most probable explanation for the 
PAE is that it is the time needed for the repair of the sub-lethal damage induced by the 
exposure to aminoglycosides. Several studies indicate that the DNA, RNA, and protein 
synthesis are all inhibited during tobramycin exposure (3, 23, 24). For Pseudomonas the 
DNA and RNA synthesis recovers rapidly during the PAE phase and a large increase in 
DNA synthesis is seen shortly before the logarithmic regrowth starts. In contrast, the 
protein synthesis was inhibited throughout the PAE phase and was resumed only after the 
bacteria were again in log-phase growth. In an earlier observation Gottfredsson et al. (25) 
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observed that tobramycin induced ultra-structural changes, such as a pattern of dense 
nuclear material and peripheral vacuoles, and that these stmctures changed during the PAE 
phase and disappeared at the end of the PAE phase. All these observations indicate that 
during the PAE phase repair mechanisms arc working in order to restore the normal 
growth rate. 
Interpretation of the PAE. As earlier indicated the PAE has been used to support 
lengthening of the dosing interval, since the PAE would prevent regrowth even when the 
antibiotic concentration is below the MIC or the drug is no longer present in the 
environment. However, during the PAE deteml.ination in vitro only short limited 
exposures of the bacterial culture to the drug are tested, where after active drug is instantly 
and completely removed from the medium. This is different from the in vivo situation, 
where the concentration of active drug declines over time. It is, therefore, suggested that 
the in vitro P AE does not necessarily reflect what happens under in vivo circumstances, 
which would caution against extrapolating them directly into clinical regimens. To 
investigate if in vitro P AE still exists at the end of a dosing interval, we simulated the 
human pharmacokinetic profile of tobramycin in an in vitro phannacokinetic model, and 
detennined the P AE at several time points during this dosing interval. The results of this 
study are discussed in Chapter 5 (13). To further investigate the difference between the 
PAE in vitro and in vivo, we also simulated the circumstances in the in vivo P AE 
experiments using animals in our in vitro phannacokinetic model. This is further discussed 
in Chapter 6 (14). 
In the last two years other investigators have likewise studied the PAE during declining 
antibiotic concentrations (37, 39), and came to the same conclusions as we did in our 
following Chapters. 
For most antibiotics and bacterial species studied so far the in vivo PAE appears to be 
longer than the in vitro PAE (Table I). Part of this discrepancy may be explained by the 
difference in methodology. In vivo the time needed for regrowth of the exposed bacterial 
culture starts to count after the concentration of the antibiotic has fallen below the MIC. 
However, the bacterial culture continues to be exposed to active dmg at concentrations 
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below the MIC. Compared to the in vitro PAE determination the measurement of regrowth 
starts after the antibiotic is completely removed or inactivated. The exposure to sub-MIC 
concentrations in vivo experiments may be at least partly responsible for the longer PAEs 
observed. The two different control growth curves that have been llsed in vivo, as 
mentioned above, do not prove that the exposed and surviving bacterial population is not 
inhibited by sub-MIC conditions, since the growth control injected into the contra-lateral 
thigh of the treated mouse was not pre-exposed to an antibiotic. It is not unreasonable to 
hypothesize that sub-MIC concentrations may very well have negligible effects on a fresh 
bacterial culture Le. the control growth curve, but have a significant effect on prc-exposed 
bacteria in the treated mice, resulting in longer PAE values in vivo. Another explanation 
for the in difference between in vitro and in vivo PAE values may be the different growth 
circumstances. The bacterial growth rate in vitro is different from in vivo. 
Before the PAE was determined using in vitro models Cars and OdenhoIt (6) described 
and discussed the difference between in vitro and in vivo PAE determination. To control 
for the possible effects of sub-MIC concentrations during the determination of the PAE in 
vivo, they developed an in vitro method to measure the postantibiotic sub-MIC effect (PA 
8ME). This in vitro method removes the antibiotic completely after the short exposure and 
thereafter re-exposes the culture to sub-MIC concentrations of the same antibiotic. This 
results in longer PA SME values, which seem more comparable to the data observed 
during in vivo PAE determination. The circulllstances under which the PA SME values are 
determined may thus be a better simulation of the in vivo situation. 
CONCLUSION 
Based on recent observations by us and other investigators (13, 14, 37, 39) it seems that 
the PAE as determined in vitro can no longer be used directly to support lengthening of 
the dose interval of aminoglycosides in clinical practice. The in vivo PAE may still have 
clinical relevance, as it describes inhibition of the bacteria under sub-MIC concentrations 
Table 1. P AE values in different studies in vitro and in vivo for comparable antibiotic concentrations. 
strain 
Antibiotic 
Tobramycin 
Gentamicin 
Arnikacin 
ND = not done. 
Postantibiotic Effect (h) 
P. aeruginosa ATCC 27853 S. oureus ATCC 25923 K Pneumoniae ATCC 43816 E. coli ATCC 25922 
vitro vivo vitro vivo vitro vivo vitro vivo 
2.9~ 3.3-5.1 (29.54) 2.0(l2) ND 2.2( 2) ND 1.6(L1 
1.9-2.6 (5.12) ND 0.9(18) 1.4(18) 1.8(18) 7.3(18) 1.2-1.6 (12.34) 
1.1_1.5(8) 4.0(8) 2.2-4.9(32.48) ND 2.6(8) 3.4(8) 1.1_1.9(8.48) 
ND 
1.9(29) 
ND 
numbers in superscript refer to the references. 
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and in vivo circumstances. However, prolonged suppression of bacterial growth may for 
the main part be due to the presence of sub~MIC concentrations of antibiotics during the in 
vivo PAE detennination. The Postantibiotic sub-MIC effect in vitro as described by 
Odenholt, Lowdin and Cars (45) seems to result in values that are better comparable with 
the in vivo PAE. 
These observations indicate that the in vitro PAE of an antibiotic has clinical relevance 
only if it exceeds the dosing interval of that specific drug, which is not the case for the 
aminoglycosides. Since the once-daily regimen of aminoglycosides is based on more 
pharmacodynamic parameters than the PAE (i.e., the concentration dependent killing, and 
a less or equal toxicity compared to multiple daily dosing) these observations need not to 
have influence on the current practice of once daily dosing. 
However, we conclude that the detennination of the in vitro P AE of aminoglycosides is 
not clinically relevant, and that the in vivo P AE is mainly due to inhibitory effects of sub~ 
MIC levels of the aminoglycosides. 
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ABSTRACT 
To detennine the postantibiotic elIect of aminoglycosides, two methods are currently being 
used to remove the test dmg: repeated washing and dilution. An enzymatic inactivation 
method of removing gentamicin and tohramycin was developed and compared with the 
dilution method. This method provides a rapid and simple alternative method of removing 
aminoglycosides which results in reliable postantibiotic effect values. 
INTRODUCTION 
Three factors are relevant when detenninlng aminogJycoside dosing schedules: MIC, the 
kinetics of bactericidal activity and the postantibiotic effect (PAE)(IO). The PAE can be 
detemlined in various ways, for example, by counting viable organisms, by measuring 
impedance or bioluminescence, by spectrophotometry, and by examining morphology (7). 
An important step in measuring the P AE is the rapid removal of antibiotic after a short 
exposure of the bacteria to the drug. In general, three methods of removing the antibiotic 
have been described: repeated washing, dilution and enzymatic inactivation (2). A specific 
problem in measuring the PAE of aminoglycosides is the marked killing capacity of these 
antibiotics, particularly at high concentrations, necessitating a substantial dilution (up to 
IOOO-fold) to eliminate antunicrobial activity. As a result, the number of viable bacteria in 
the sample falls below the limit of detection (4). The second method used for removal of 
aminoglycosides is repeated washing. Although this method does not influence the limit of 
detection, washing itself may cause a temporary reduction in the rate of bacterial regrowth 
(2,9), possibly resulting in less reliable PAE values. In addition, washing is timewconsmning. 
The third method used for antibiotic removal is enzymatic dmg inactivation. So far, the use 
of this method has been restricted to the ~-lactam antibiotics. In the present study an 
enzymatic method was developed for inactivation of the aminogtycosides gentamicin and 
tobramycin. To validate this new method, we compared the results of the enzymatic 
inactivation method with those of the generally used dilution method. 
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MATERIALS AND METHODS 
Bacterial strains, media and antibiotics. The strains used for measurement of the PAE by 
the enzymatic inactivation method were Staphylococclis am'ells ATCC 29213, Escherichia 
coli ATCC 25922, Klebsiella pneumoniae ATCC 43816, and Pseudomonas aeruginosa 
ATCC 27853. MICs were detennined by a standard macrodilution method with Mueller-
Hinton broth (Difco, Amsterdam, The Netherlands), supplemented with Ca" (25 mg/I) and 
Mg" (l2.5mg/l)(MHBs)(8). The MICs of gentamicin (Schering-Plough, Amstelveen, The 
Netherlands) and tobramycin (Eli Lilly and Company, Nieuwegein, The Netherlands) for the 
strains tested were 1.0 and 0.5 mg/I for S. aurellS, 1.0 and 1.0 mg/I for E. coli, 0.5 and 0.5 
mg/I for K plleumolliae and 1.0 and 0.5 mg/I for P. aerllgillosa, respectively. E. coli R 176 
(a clinical isolate of unknown source, resistant to gentamicin and tobramycin and susceptible 
to netilmicin and amikacin) was used for the extraction of an aminoglycoside-acetylating 
enzyme [AAC(3)-1l] (6). 
Extraction of the enzyme. E. coli R 176 was inoculated from a fresh ovemight culture into 
Todd-Hewitt broth (Oxoid, Basingstoke, Hampshire, England) containing either gentamicin 
(5 mgll) or tobramycin (5 mg/I) and incubated while shaking (200 rpm) at 37°C until the 
optical deru;ity at 660 mn was 0.63. After centrifugation (15 min at 6,000 x g and 4°C), the 
pellets were resuspended in phosphate-buffered saline and bacteria were dismpted by 
ultrasonic treatment at an amplitude of 14 (Soniprep; MSE, Bughborough /Leics, Great 
Britain) 10 times for lOs each while cooling on ice for 10 s between treatments. The cell 
debris was then centrifuged for 2 h at 100,000 x g (L-70 centrifuge; Beckman, Palo Alto, 
Calif.). After the addition of dithiothreitol (Sigma, St. Louis, Mo.) to a fmal concentration of 
5mM, the supernatant was filtered (0.45-llm-pore-size filter; Schleicher and SchueH, ts_ 
Hertogenbosch, The Netherlands) and stored as a stock solution at -80°C. 
Enzymatic activity. The number of units of activity in the enzyme preparation was 
detennined in tobrarnycin solutions of 10 and 20 mg/I in MHBs at 37'C. There was no 
difference in the initial rates of enzyme activity as measured at both tobramycin 
concentrations (data not shown). The enzymatic activity was further detennined under 
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several sets of enviromnental conditions: four tobramycin solutions of 5 mgll were made in 
MHBs at pH 7.2 (method 1), MHBs from a 24-h culture of S. aureus at an adjusted pH of7.2 
(method 2), MHBs from a 24-h culture of S. aureus at pH S.3 (method 3), and MIllis from a 
logarithmic culture of S. aureus at pH 7.2, exposed for I h to S mg of tobramycin per liter 
(method 4). To each solution were added 0.02 U of enzyme and 0.2 mmol of acetyl 
coenzyme A, and the solutions were incubated in a waterbath at 37'C while shaking (200 
rpm). Samples were taken at time zero, lOs, 1 min, and 5 min and inunediately heated to 
90"C to inactivate the enzymes. Tobramycin concentrations were detennined by a standard 
microbiological agar diffusion test using S. allreus ATCC 29213 as a test strain. The 
enzymatic activity of the stock solution stored at -80°C was tested every month. 
Bacterial growth interaction. In order to detect a possible influence of the enzyme and 
acetyl coenzyme A on ~he bacterial growth rate, growth curves were detennined by a 
standard method (1). Briefly, a logarithmic culture of each strain, with an inoculum of 
approximately S x 10' CFU/ml, was incubated with om U of enzyme per ml and 0.2 nunol 
acetyl coenzyme A (9S%, prepared enzymatically, Sigma) per ml. Samples were taken at 0, 
1,2,3,4,6,24 h. Control growth curves were obtained similarly, but the enzyme and acetyl 
coenzyme A were not added to the cultures. 
PAE determination. To detemline the P AE, a logarithmic culture of approximately 5 x 
106 CFU/ml in MHBs was exposed to gentamicin or tobramycin at a concentration of four 
times the MIC for 1 hat 37'C. After the incubation period, the antibiotic was removed by 
two methods: SOO-fold dilution in pre-warmed MHBs (2) and enzymatic inactivation. For 
enzymatic inactivation 0.01 U of enzyme per ml and 0.2 mmol acetyl coenzyme A per ml 
were added to the samples. The control cultures, which were not exposed to the 
antibiotics, were treated similarly. The cultures were further incubated for 6 h at 3rC. 
Samples were taken each hour and diluted serially lO-fold in cold sterile saline on ice. 
Each dilution was plated on tryptone soy agar (Oxoid) and incubated ovemight at 37'C. To 
decrease the variability at low colony cOllnts, near the lower limit of detection, 20~ml 
samples were taken from the cultures at 0, I, 2, and 3 h, treated by the dilution method, 
and filtered with the sensor II Milliflex-IOO system (O.4S-~m-pore-size filter; Millipore 
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Corporation, Bedford, Mass.). At 4 to 6 h, I-ml samples were plated on tryptone soy agar 
and incubated overnight at 37°C. Each experiment was perfonned six times. The PAE was 
defined as described by Craig and Gudmundsson (2) as PAE ~ T - C, where T is the time 
required for the CFU count of the antibiotic-exposed culture to increase 1 logiO unit above 
the count immediately after drug removal and C is the corresponding time for the control 
cultures. The SAS computer package was used for statistical analysis (11). 
RESULTS 
Enzymatic activity. Extraction of enzyme from 1 Iiter of bacterial culture yielded 90 ml ofa 
solution containing 0.1 U of enzyme per ml (standard deviation ~ om, n ~ 3). Fig. I, a plot 
of the enzymatic activities under several sets of environmental conditions, shows no 
differences among the enzymatic activities in MHBs at pH ~ 7.2 (method 1), MHBs from a 
24-h culture of S. allrells at an adjusted pH of 7.2 (method 2), and in MHBs from a loga-
rithmic culture of S. aureus at pH 7.2 (method 4). The enzymes were almost inactive in 
MIllis of a 24-h culture of S. alll'ellS at pH 5.3 (method 3). The results show that the 
enzymatic solution was able to inactivate the tobramycin under several test conditions, 
including the simulation of the P AE test conditions (method 4). The enzymatic stock 
solution stored at -80°C was stable for at least 2 years. 
PAE determinations. No significant differences were found between the growth curves of 
the strains in the presence or in the absence of the enzyme and acetyl coenzyme A (data not 
shown). The mean P AE values determined by the dilution and enzymatic inactivation 
methods are shown in table 1. The difference between the results of the two methods is 
expressed as the mean change in P AE (8P AE = P AEdi1utioo - PAECIlZ)me for each individual pair 
of experiments) with 95% confidence intervals. nlere was no significant difference between 
the values determined by the two methods. The observed arninoglycoside PAEs for both 
methods were highly comparable, and differences were not statistically significant. The 
between-sample, between-day variabilities of the PAE values, expressed as the mean 
coefficient of variation of the four strains, was 7.5% (gentamicin) and 9.3% (tobramycin) for 
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the dilution method and 8.3% (gentamicin) and 9.2% (tobramycin) for the enzymatic 
inactivation method. 
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Figure 1. Enzymatic activity, shown as the removal of tobramycin over lime under different envirorunental 
conditions, i.e. in MHBs at pH 7.2 (0). in MHBs of a 24-h overnight culture of S. aurells at pH 5,3 (.), in 
MHBs ofa 24-h overnight culture of S. aureus at an adjusted pH of7.2 (Y), and in MHBs ofa logarithmic 
culture of S. alfre/fs at pH 7.2, exposed for I h to a 5 mgll tobramycin solution (0) (simulating PAE test 
conditions). Data are means ± standard deviations from four experiments. 
DISCUSSION 
P AE has been used to support the use of alternative dosing schedules, i.e. larger doses with 
longer intervals (5, 12). Because of the supposed significance of the P AE, the method for 
measuring the P AE has to be as accurate as possible. There was no significant difference in 
PAE values detennined by the above-described enzymatic inactivation method and the 
dilution method at a concentration of four times the MIC. In addition, the PAE values found 
were comparable to those mentioned in literature (2, 3). An important drawback of the 
dilution method is the relatively high limit of detection, and in order to get reliable colony 
counts, a large sample must be filtered because of the 500-fold dilution. In contrast, with the 
enzymatic inactivation method, no problems were encountered with respect to the limit of 
detection. 
Table 1. In vitro PAEs obtained for gentamicin and tobramycin dilution and enzymatic inactivation. 
Gentamicin Tobramycin 
PAE' (h) PAE' (h) 
Strain Dilution Enzymatic IIPAEb Dilution Enzymatic IIPAEb 
inactivation inactivation 
S. aureus ATCC 29213 2.4 (0.1) 2.5 (0.1) -0.1(-0.30-0.04) 2.0 (03) 2.0 (02) 0.0 (-0.33-026) 
E. coli ATCC 25922 1.6 (0.2) 1.5 (02) 0.1(-0.04-0.18) 1.6 (0.1) 1.6 (0.2) 0.0(-029-022) 
K pneumoniae ATCC 43816 2.1 (0.1) 2.1 (02) 0.0(-023-0.13) 2.2 (0.1) 2.2 (0.2) 0.0(-0.29-029) 
P. aeruginosa ATCC 27853 1.9 (0.1) 1.9 (0.1) 0.0(-0.30-0.17) 2.1 (0.1) 2.0 (0.1) 0.1(-0.10-0.23) 
overall 0.0(-0.12-0.03) 0.0(-0.10-0.1 0) 
a Data are mean PAEs after a I ~h exposure to four times MIC:- of the antIbiotics, based on six experiments. Values in parenthesis are standard deviations 
b Data are mean differences in PAEs obtained by the dilution vs. the enzymatic inactivation methods in paired parallel experiments. Values in parenthesis are 95% 
confidence intervals. 
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We conclude that the enzymatic inactivation method is a simple. rapid and more accurate 
method of measuring P AEs of gentamicin and tobramycin, especially at high concentrations. 
With the appropriate enzymes, the same method should be applicable for the study of P AEs 
of other aminoglycosides. 
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ABSTRACT 
The kinetics of the Postantibiotic effect (PAE) during one dosing interval of tobramycin 
against Staphylococcus aureus and Pseudomonas aeruginosa was investigated. We 
detennined the PAE at different time points during this dosing interval of 12 h in an in vitro 
phannacokinetic model, simulating human phannacokinetics, in which the half-life of 
tobramycin was adjusted to 2.4 ± 0.2 h. Using an enzymatic method to inactivate 
tobramycin, we detennined PAEs in samples extracted from the model at J, 5, 8, 12 It, 
corresponding with tobramycin concentrations of 20, 5, 2, and I times the MIC of the test 
organism. The PAE decreased significantly from 2.5 h at I h to ° h at 12 h. No change in 
MIC was observed for the strains during the experiments. We conclude that the P AE 
decreases with decclining tobramycin concentrations during a 12-h dosing interval and 
completely disappears after the concentration has reached the MIC for the test organism. On 
the basis of these observations, the emphasis that is placed on the PAE in discussions about 
the optimal dosing interval in amino glycoside therapy is questionable. 
INTRODUCTION 
Three factors are relevant when detemlining an aminoglycoside dosing schedule, i.e., the 
susceptibility of the bacteria (MIC), the kinetics of antibacterial activity and the 
postantibiotic effect (P AE) (2). The P AE is usually determined after I or 2 h of exposure to 
antibiotics at 4 to 5 times the M1C (4xMIC) to 5xMIC followed by inullediate removal or 
inactivation of the antibiotic. Partly on the basis of these data, intennittent therapy of 
aminoglycosides with longer dosing intervals, such as once- or twice-daily dosing, has been 
introduced into clinical practice (7, 8, 16, 19) since the PAE supposedly would prevent 
bacterial growth when drug concentration in serum and tissue fall below the MIC (I). 
However, the P AE is detennined in vitro after I or 2 h of exposure to fixed antibiotic 
concentrations while in the clinical setting aminoglycoside concentrations decline over time 
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with an elimination half-life of several hours. It could well be that the PAE has disappeared 
at the time the concentration falls below the MlC, thus losing its clinical relevance. 
In the present study, the P AE was determined during one dosing interval of tobramycin in a 
pharmacokinetic model simulating human phannacokinetics. The P AE was determined at 
four time points during tlus dosing interval of 12 h to study the kinetics ofthe PAE itself and 
to determine wheUler the P AE is still present at the time the drug concentration falls below 
the MIC for the infecting organism. 
MATERIALS AND l\IETHODS 
Bacterial strains, antibiotics and media. The strains used for this experiment were 
Staphylococcus aureus ATCC 29213 and Pseudomonas aeruginasa ATCC 27853. The MIC 
of tobramycin (Eli Lilly and Company, Nieuwegein, The Netherlands) was 0.5 mgll for S. 
aUl'eus and 0.5 mgll for P. ael'uginosa, detennined by both a standard macrodilution method 
in Mueller Hinton broth supplemented (MHBs) with Ca" (25 mg/I) and Mg" (12.5 mg/I) 
(Difco, Amsterdam, The Netherlands) and an agar dilution method (15). 
Pharmacokinetie model. TIle model used, was described previously in detail (14). Briefly, a 
two-compartment model consisting of one central compartment and four peripheral 
compartments consisting of disposable dialyzer units (8123, Baxter, Utrecht, The 
Netherlands) was used to expose the bacteria in the peripheral compartments to changing 
antibiotic concentrations, mimicking human phannacokinetics. A volume of 150 rul of a 
logarithmic-phase culture of S. aUl'eus or P. ael'uginosa at a concentration of approximately 
\07 CFU/ml was injected into the peripheral compartments starting at ° h, tobramycin was 
infused into the central compartment for I h with an infuser (Braun, Melsungen AG, 
Germany) providing a total dose of 15 mg/I, resulting in a peak concentration of 
approximately \0 mg/I at I h. The half-life of tab ran lye in was adjusted to approximately 2 h. 
To detemline the tobramycin concentration by a fluorescence polarisation immuno assay 
using a TDxFLx device (Abbott Diagnostic Division, Amstelveen, The Netherlands) and 
colony counts, samples were taken at 0,10, and 30 min, and 1,5,8, and 12 h from both the 
central and peripheral compartments. To detemline the killing rates for the two strains the 
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samples were washed two times with cold saline, diluted serially IO-fold in cold saline and 
plated on tryptone soy agar plates (Dxoid, Basingstoke, Hampshire, England) for colony 
count detennination. Control growth curves were also detennined in the phannacokinetic 
model. 
PAE determination. To determine the PAE, samples were taken at 1, 5, 8 and 12 h, 
corresponding with estimated tobramyein concentrations of20xMIC (peak), 5xMIC, 2xMIC 
and lxMIC (trough), respectively. An enzymatic method for the removal oftobramycin was 
used (6). Briefly, a I-ml sample was added to 9 ml of MHBs at 37°C. To this medium a 
tobramycin-acetylating enzyme [AAC(3)-Il] (12) and acetyl coenzyme A were added, 
resulting in the inactivation of tobramycin within 5 min. P AE was defined according to 
Craig and Gudmundsson (3) as follows: P AE ~ l' - C, where l' is the time required for the 
CFU count in the test culture to increase 1 10gIO above the count immediately after drug 
removal and C is the corresponding time for the controls. From the P AE regrowth cultures, 
samples were taken at 0, 1,2, 3, 4 and 6 h and diluted serially in cold saline. Each dilution 
was plated on TSA and incubated overnight at 37°C. 
Control growth curves were determined in the pharmacokinetic model, which was treated 
similarly as the test cultures werc, only without the addition of tobramycin. For the 
detemlination ofPAE control curves, samples were taken at 0, 1, 5, 8 and 12 h and diluted in 
MHBs at 37°C tmtil the inoculum had the sante starting CFU per milliliter as the test strain 
did at that time, thus ruling out the possibility of an inoculum effect. As a control, I ml of 
this inoculum was treated as the test strains were by adding tobramycin~acetyJating enzyme 
and acetyl coenzyme A. The experiment was repeated four times in duplicate for each strain. 
MICs were deternlined by a standard agar dilution method (15) for the strains isolated from 
the samples at 1,5,8, and 12 h. 
Statistical analysis. The SAS computer package (18) was used for statistical analysis. The 
PAE values at four different time points were analyzed using the Tukey-Kramer multiple-
comparison test and the values determined for regrowth during the killing curve 
determination was analyzed by repeated measurement analysis of variance (ANDV A). 
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RESULTS 
Antibiotic concentrations and pharmacokinetics. TIle mean concentration ± standard 
deviations for tobramycin in the four experiments in the pharmacokinetic model are shmvn 
in table I. The peak and trough concentrations as well as the half-lives did not vary 
significantly between separate experiments. The actual measured half-life ± standard 
deviation was 2.4 ± 0.2 h, which is slightly longer than the adjusted half-life, but is still 
within the range of half-lives found for patients. 
Killing kinetics. Killing and regrowth curves of S. aureus and P. ael'uginosa were 
determined at 1, 5, 8, and 12 h. A representative exanlple ofa killing and a regrowth curve of 
both strains in the pharmacokinetic model is shown in Fig. 1. The figure also shows an 
example of a control growth curve and its regrowth curve, which were determined 
separately. The regrowth which is seen in the killing curve in the model is significant over 
time from 1 h to 12 h (p = 0.0022) for P. ael'lIginosa but not for S. alll'ellS during all 
experiments. 
PAE determination. A summary of all PAEs detemlined at all time points is given in Table 
l. For both S. GlIl'eliS and P. aeruginosa, the P AE after a I-hour exposure at a tobramycin 
concentration of 20xMIC was approximately 2.5 h. The PAEs determined at 12 h were 
essentially 0 h. Thus, the PAE value of tobrarnycin decreases rapidly over time in 
concordance with the cOllcentration-versus-MIC ratio in this phannacokinetic model. The 
MICs oftobramycin for S. alll'eliS and P. ael'lIgillosa isolated from the samples at 1,5,8 and 
12 h were 0.5 mg/I. No genotypical resistant strains were isolated during the experiments. 
DISCUSSION 
In this study, we describe that the PAE decreases to 0 h during one dose interval of 
tobrarnycin. P AEs determined at the peak concentration of about 10.6 mg/l were 
approximately 2.5 h for both S. alll'ellS and P. aerllgillosa, slightly higher than those found in 
literature when detemlined at 4xMIC to 5xMIC (3). The PAE at the peak concentration are 
determined after an exposure of 1 h, but at a final concentration of20xMIC. This could 
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Figure 1. Representative cUlves for a control growth (.), control regrowth (0), killing (A) and killing 
regrowth (a) curves of S. al/rellS (a) and P. aeruginosa (b) as detennined during all experiments in the 
pharrnacokinetic model are shmYJ1. For these curves, samples for PAE measurement were taken at 8 h. PAE can 
be detennined as PAE = T ~C. according to Craig and Gudmundsson (3) (see text for details). 
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Table 1. Tobramycin PAEs for S. GurellS and P. aerllgillosa. 
Time 
(h) 
5 
8 
12 
Tobramycin 
conen" (mgll) 
10.6 (1.1) 
2.6 (0.4) 
1.1 (0.2) 
0.5 (0.1) 
Tohramycin 
concn/MIC 
21.2 
5.2 
2.2 
1.0 
PAEb (h) for: 
S. alfrellS P,aeruginosa 
2.6 (1.8-3.3) 2.5 (1.9-3.1) 
0.7 (0.2-1.2)' 0.9 (0.6·1.2)' 
0.6 (0.1-1.0)' 1.5 (1.1-1.9)' 
0.1 (-0.1-0.3)' -0.3(·0.6·0.0)' 
• Data are means of four separate experiments perfonncd in duplicate. Values in parentheses are standard 
deviations. 
b Data are means of four separate experiments perfonned in duplicate. Values in parentheses are 95% 
confidence intervals, 
~ Significant decrease compared to the PAE at I h. 
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explain the slight difference relative to the P AEs detennined at 4xMIC to 5xMIC. During the 
dosing interval, however, PAEs decreased to 0 h at t~12 h, i.e., when the antibiotic 
concentration is approximately the MIC. Apparently, during a half-life of 2.4 h the 
bacteriaare able to recover more rapidly than the time it takes for the concentration of 
tohrarnycin to decrease to the MIC ofthese strains. 
The P AEs dctennined during in vivo experiments in animal models are produced in rodents 
with a short antibiotic half-life (significantly shorter than that for humans) (3). But if the 
half-life for the rodents is adjusted to that for humans by inducing renal impairment the P AE 
values become even longer (4), so the half-life carmot be used as an explanation for the 
declining of the PAE in the in vitro model. 
The P AE not only declines during a dose interval, but also disappears after multiple 
antibiotic exposures (9, II, 13, 17). However, in these studies (9, 11, 13, 17) the bacterial 
cultures were repeatedly exposed to the same concentration of antibiotic for a short period of 
time (2 h). 
TIle killing curve of P. aeruginosa as detennined in the model (Fig. 1) shows a significant 
log-linear trend (p<O.OOOI) from 5 to 12 h. At the beginning of the dosing interval, bacteria 
are killed rapidly, followed by a lag-phase induced by tobrarnycin (from 1 to 5 h) during 
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which the nwnber of CFU per milliliter does not change significantly in the model. During 
the ensuing period the bacterial growth accelerates, leading to a significant increase of CFU 
per milliliter from 5 to 12 h. TIus could be due to regrowth of phenotypical resistant 
subpopulations, since growth was observed at tobramycin concentrations exceeding the 
MIe. After subculturing, we did not observe an emergence in genotypical resistance to 
tobramycin in the organisms. The occurrence of phenotypically resistant subpopulations 
cannot be excluded, as plating the samples on tobramycin-containing agar was not 
performed. Thus we carnlOt confirm the observation of Karlowsky et al. (IO) of a MIC 
reversion time. The fact that regrowth of p, aerug;nosa at tobramycin concentrations 
exceeding the MIC supports the argwnent that keeping the tobramycin concentration above 
the MIC is not the most important parameter of efficacy. TI,e fast initial killing caused by 
relatively lugh concentrations of aminoglycosides is possibly one of the most important 
factors dnring therapy with these drugs. Another reason for this regrowth phenomenon could 
be the difference in inoculwn sizes used for the MIC determination and for the PAE 
determination, 5 x lOS and 1 x 107 CFU/ml, respectively, since the use of a higher inoculum 
could result in a lugher MIC (the true MIC). The MIC detemlined with an inocuhun of 10' 
CFUlml was 1.0 mgll for both strains (data not shown). This however only explains the 
regrowth of P. aeruginosa observed after 8 h, when tobramycin concentration decreases 
below 1 mg/1. 
In order to optimize the use of amilloglycoside antibiotics, results of several studies 
investigating their pharmacodynamic parameters predicting efficacy (1, 9, 10) and 
toxicological effect (6) are being used. Dosing schedules have been detemuned by matching 
the pharmacokiuetic profile in normal volunteers to the dntg's activity in vitro (20). The 
decrease of the P AE to 0 h dnring a complete dosing interval might deflate the importance 
which is given to the P AE in discussion about the dosing interval in anunoglycoside therapy. 
TIle results of this study do not argue against a change of three-daily to once-daily dosing 
schedules, but they do question the role of the PAE in its rationale. Thus, once-daily therapy 
can still be favored on the basis of reduced toxicity (6) and higher peak levels, producing a 
higher initial killing rate that may well be lughly clinically relevant (10). 
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In conclusion, the present study describes a significant decrease in P AE from 2.5 h to 0 h 
during one dosing interval of tobramycin. The important impact which is ascribed to the 
P AE in discussions about the lengthening of the dosing interval is therefore questioned. 
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ABSTRACT 
The influence of half-life on the postantibiotic effect (P AE) of tobramycin against 
Pseudomonas aerugillosa and Staphylococcus aureus was investigated during one dosing 
interval. Tobramycin half-lives of 0.5 to 2.5 h were simulated in an in vitro model and the 
PAE was determined by an enzymatic inactivation method at different time points, i.e., 
when the tobramycin concentrations were 20 x, 5 x, and 1 x the MIC. At the time point 
during therapy that the tobramycin concentrations had declined to I x the MIC, at a 
tobramycin half-live of 0.5 h, the times of the PAEs were approximately 0.7 and 1.7 h for 
P. aerugillosa and S. aureus, respectively, and disappeared completely at half-lives 
corresponding with those found in humans (i.e. 2 to 2.5 h). The PAE itself cannot be fully 
explained by the presence of free intrabacterial tobramycin or emergence of resistant 
subpopulations. The explanation for the disappearance of the PAE during the dosing 
interval may therefore be explained by the repair of sublethal damage. Since the standard 
method of detennining the PAE in animal models is somewhat different from the method 
used for measurement of the P AE in vitro, the conditions under which the P AE is 
measured in vivo were also simulated in the in vitro model. This resulted in PAEs longer 
than those found by the standard method of obtaining in vitro PAE measurements. We 
conclude that the PAE for tobranlycin, as determined by conventional in vitro methods, 
has virtually no clinical importance. P AEs determined in vivo may have some clinical 
relevance, but they are probably primarily caused by sub-MIC effects. 
INTRODUCTION 
The clinical relevance of the postantibiotic effect (P AE) as detemlined in vitro remains 
questionable. The main problem is that the P AE is measured as delayed bacterial growth 
after short on-off exposure to an antibiotic for I or 2 h (4). Such exposure does not reflect 
the situation in humans under clinical conditions, where bacteria are exposed to antibiotic 
concentrations that decline only slowly over time, with half-lives up to several hours. 
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Nevertheless, the PAE has been used to support the lengthening of the dosing interval for 
aminoglycosides (14, IS, 20, 22), since it is assumed that the PAE would significantly 
delay bacterial regrowth after the antibiotic concentration falls below the MIC (2). 
Recently, we showed that the PAE completely disappeared during one dosing interval of 
tobramycin simulated in an in vitro pharmacokinetic model (S). The PAE determined at 
the peak concentration (20 x MI C) correlated well with the P AE measured under standard 
conditions, but it declined to zero at the end of a dosing interval. There are several 
explanations for the PAE and the disappearance thereof. The P AE itself can be explained 
by several hypotheses, e.g. sublethal damage in the bacteria due to antibiotic exposure and 
that needs to be repaired before the normal growth rate returns. Another explanation might 
be a growth retardation due to free tobramycin which remains inside the bacteria and 
which is not removed during the washout phase of the PAE experiment. On the other 
hand, the disappearance of the PAE, which was observed during one dosing interval of 
tobramycin (5), may be a result of the outgrowth of resistant subpopulations of bacteria. 
Alternatively, the phenomenon may be due to slow diffusion of tobramycin out of the 
bacteria, or may be a result of a fast repair process in the bacteria. These last processes 
may happen in the foci of slowly declining antibiotic concentrations of a dosing interval in 
vivo, while the fast washout of tobramycin during the detemlination of the PAE in vitro 
may be too short for these processes to start and have an effect. The P AE may thus be an 
in vitro phenomenon that does not occur in vivo. 
Thus, the most striking difference between the PAE determination in vitro and in vivo is 
the fast elimination of the antibiotic (Le. a very short half-life) during in vitro experiments. 
In order to study the effect of the half-life on the PAE of tobramycin, we determined the 
P AE during one dosing interval of tobramycin in an in vitro phannacokinetic model, 
simulating tobramycin half-lives in the range of O.S to 2.S h. The P AE was determined at 
three time points during the interval corresponding to tohramycin concentrations of 20 x 
the MIC, S x the MIC, and 1 x the MIC. Furthermore, we looked for the emergence of 
resistant subpopulations of bacteria during these PAE determinations, and the hypothesis 
of the diffusion process was investigated. Finally, to determine whether the larger PAE 
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found in vivo compared to that found in vitro (3) is due to differences in the methods used, 
the conditions of both methods were simulated in the in vitro model. 
MATERIALS AND METHODS 
Bacterial strains and media. The strains used were Staphylococcus aureus ATCC 29213 
and Pseudomonas ael'uginosa ATCC 27853. Mueller-Hinton broth (Difco, Amsterdam, The 
Netllerlands) supplemented with Ca" (25 mg/l) and Mg" (12.5 mg/I) was used in all 
experiments (MHBs). All bacterial sanlples were plated on Trypticase Soy Agar (TSA; 
Oxoid, Basingstoke, Hampshire, England). The M1C of tobramycin was 0.5 mg/I for both 
the S. aureus strain and the P. aeruginosa strain, as detemlined by a standard macrodilution 
method with MHBs (19). 
Antibiotic. Tobramycin was provided as a solution with a concentration of 10 g/I (Eli Lilly 
and Company, Nieuwegein, The Netherlands). Tobramycin concentrations were assayed by 
a fluorescence polarization immunoassay using a TDxFLx instrument (Abbott Diagnostic 
Division, Amstelveen, The Netherlands), which had concentration range of 0 to 10 mg/I and 
a coefficient of variation < 6%. 
Pharm.cokinetic model. The model used was described previously in detail (18). Briefly, a 
t\vo~compartment model consisting of one central compartment and four peripheral 
compartments including disposable dialyzer units (ST23, Baxter, Utrecht, The Netherlands) 
was used. The bacteria were exposed in the peripheral compartments to a changing antibiotic 
concentration that mimicked the pharmacokinetics of tobramycin; the pharmacokinetic 
profile depended on the half-life chosen for a given experiment. 
A volume of 150 mI of a logarithmic phase culture of S. aUl'eus or P. aeruginosa 
(approximately 10' CFU/ml) was injected into the peripheral compartments. At time zero a 
total dose of 15 mg tobramycin was infused into the central compartment over I h using an 
infuser (Braun, Melsungen AG, Gemmuy); this resulted in a peak concentration of 
approximately 10 mg/l at 1 h. During the first hour (the infusion time) the half-life was 
adjusted to 2 h; thereafter, the half-life of tobramycin was set to 0.5, I, 1.5,2, or 2.5 h, as 
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indicated. These different half-lives resulted in a time above the MIC (T"ncl in a range of3.1 
to 11.9 h, and an area under the concentration-time curve (AVC) of 12.3 - 40.2 mg.h/l. 
Killing kinetics. To determine the tobramycin concentration and bacterial CFV, samples 
were taken from each peripheral compartment at time zero, 30 min, 1 h, and at time points 
when the tobramycin concentrations were 5 x the MIC and I x the MIC. To detennine the 
killing rate, samples were washed two times with cold phosphate-buffered saline (PBS), 
diluted serially 10-fold in cold PBS and plated on TSA plates for colony count 
detennination. 
PAE determination. To deteruline the PAE at different concentrations, samples of 10 ml 
were taken at the peak concentration (20 x MIC) and at the time points corresponding to 
tobramycin concentrations of 5 x the MIC and I x the MIC. An enzymatic method for the 
inactivation of tobramycin was used (6). Briefly, \0 ml of each sample was added to a 
freshly prepared solution of tobramycin-acetylating enzyme AAC (3)-11 (16) and acetyl 
coenzyme A, resulting in the inactivation of tobramycin within 5 min. A volume of 5 rol of 
this solution was placed on ice immediately for one night, to allow free intrabacterial 
tobramycin to diffuse out of the bacteria, where it would be inactivated by the enzymes. The 
rate of regrowth in the remaining 5 ml was determined, and the PAE was defined as P AE ~ 
T - C, where T is the time required for the numbers of CFU in the test culture to increase 1 
10glO above Ule count immediately after drug removal and C is the corresponding time for the 
controls (4). Samples were taken from the PAE regrowth cultures at 0, 1,2,3,4, and 5 h and 
serially diluted in cold PBS. Volumes of 0.25 and 0.1 ml were plated on TSA for the 
undiluted samples and for the samples with other dilutions, respectively, and the plates were 
incubated at 37'C overnight for P. ael'lIginosa and 48 h for S. allrells. The undiluted samples 
were also plated on Iso-Sensitest agar plates (Oxoid), containing tobramycin concentrations 
of 0.5, I, 2, 4, 8 mgll, to detect Ule presence of resistant subpopulations. Control growth 
curves were determined in the same in vitro phannacokinetic model, but without the addition 
oftobramycin. Control samples were taken at 0,1,2,3,4,5,6,8,10, 12, 18, and 24 h, and 
in the tests with tobramycin at time points when the tobramycin concentrations were 5 x the 
MIC and I x the MIC. 11le control samples were diluted in MHBs (at 37°C) until the 
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inoculum had the same starting numbers ofCFU per milliliter as the test strain at this time. A 
volume of 1 0 Illl of this control inoculum was treated as described above for the test cultures. 
All samples that had been placed on ice ovemight were quickly brought to 37'C as described 
previously (7, 8), and regrowth curves were performed as described above. All experiments 
were perfonned in duplicate on at least two separate occasions. 
Simulation of in vivo P AE in mice with renal impairment. To study the differences 
between the PAE detennined in vitro versus in vivo, experimental conditions were simulated 
as described by Craig et al. (3). Briefly, in their experiments renal impainnent was induced 
in neutropenic mice, resulting in an amikacin half-life of93.3 to 121 min, thus approaching 
pharmacokinetics in humans. For the in vitro simulation of the pharmacokinetics in such 
mice, the experiments were started as described above, and aftcr I h the half-life was 
adjusted to 1.5, 2.0, or 2.5 h. During these experiments no enzymatic inactivation of the 
tobramycin was used, since in the in vivo experiments the PAE is defined as the time the 
culture needs to grow I log" after the antibiotic concentration declined below the MIC (13). 
Samples were taken from the peripheral compartments ofthe in vitro model at 0, I, 2, 4, 6, 8, 
10, 12, 14, 16,24, and 28 h, and at the time point that the tobramycin concentration was I x 
MIC. To determine the numbers of CFU per milliliter, samples were washed twice in cold 
PBS, diluted serially IO-fold in cold PBS and plated onto TSA plates. Control growth curves 
were detennined with the model, and at the same time points when the test cultures had a 
tobramycin concentration of 1 x the MIC, samples were taken and diluted in prewarmed 
MHBs until the starting inoculum was equal to the starting inoculum of the test culture at 
that time point, as described above. Regrowth of the control was determined outside the 
model in a test tube containing 10 ml. The PAE was detennined as described by 
Gudmundsson et al. (13) by the formula PAE ~ T - C - M, where M represents the time the 
concentration in serum exceeds the MIC. 
Statistics. The peak concentrations, the half-life times, and the P AE data were analyzed 
using the Tukey-Kramer Multiple Comparisons test, one-way Analysis of Variance and a 
test for linear trend between column means with the Instat statistics program (I2). A P value 
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,; 0.05 (two tailed) was considered significant. Correlation between the P AE and other 
parameters was detennined using the parametric correlation test of Pearson. 
RESULTS 
Antibiotic concentrations and pharmacokinetics. The observed peak concentration 
(mean ± standard error of the mean [SEMJ) and the concentrations at time points when the 
tobramycin concentrations were 5 x the MIC and I x the MIC were 10.6 ± 0.3, 2.8 ± 0.1, 
and 0.7 ± 0.1 mg/I, respectively. The tobramycin half-lives (mean ± SEM) during the 
various experiments were 0.6 ± 0.1, 1.1 ± 0.1, 1.7 ± 0.1, 2.2 ± 0.1, and 2.6 ± 0.1 h. 
Killing kinetics. Killing and regrowth of P. ael'uginosa and S. aureus were determined in 
the phannacokinetic model during all experiments. A representative example of the killing 
and regrowth curve of both strains exposed to tobramycin with a half-life of 1.5 h is shown 
in Fig. 1. Figure I also shows an example of a control growth curve and the control 
regrowth curve. If the control regrowth curve is compared with the control growth curve in 
the model, it seems to have a short lag phase before regrowth begins exponentially. 
PAE determination. A summary of all mean ± SEM PAEs detennined in the various 
experiments is given in Fig. 2. The mean ± SEM P AEs for P. aeruginosa and S. aureus 
determined at the peak concentration (20 x the MIC) were 2.0 ± 0.7, and 1.8 ± 0.5 h, 
respectively, which are comparable to those published previously (5), and were not 
significantly different between the different experiments. The PAEs for P. ael'uginosa at a 
tobramycin concentration of 5 x the MIC depended on the tobrarnycin half-life chosen. A 
significantly decreasing linear trend (p<O.OOO I) was found, from a mean ± SEM P AE of 
2.0 ± 0.2 h to one of 0.8 ± 0.3 h, for increasing half-lives of 0.5 and 2.5 h, respectively. At 
a concentration of I x the MIC, the P AE was around the 0.7 h for the half-lives of 0.5 to 
2.0 h but completely disappeared if the tobramycin half-life was set at 2.5 h (Fig. 2). In 
experiments with S. aureus the PAEs at a concentration of 5 x the MIC, the PAEs showed 
no significant difference for half-lives of 0.5, 1, and 1.5 h, but a significant decrease in the 
PAEs was observed for half-lives of2 and 2.5 h (p<0.001). At a concentration of I x the 
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MIC the PAEs for S, aureus decreased from 1.7 ± 0,5 h to 0,1 ± 0,2 h, resulting in a 
significant linear trend (p<0.000 I). The data presented in Fig. 2 also indicate that the 
PAEs for both p, aeruginosa and S, aureus decline during a dosing interval. For p, 
aeruginosa the PAE was a significant linear declining trend (O,OOOI<p"O.OI) during the 
dosing interval for half-lives of 1.0 to 2,5 h. For S, aureus the PAE also decreases during 
the dosing interval, hut a significant linear decrease in PAE is observed only for half-lives 
of2.0 and 2.5 h (p = 0.004, p<O.OOOI, respectively). 
The linear declining trend seen with an increase in the half-life is also shown by the good 
correlations between the AUC and the PAE. The AUC determined for the time period until 
the concentration declines below the MIC correlates well with the P AE at I x the MIC for 
S, aureus (r = -0,99, p<O.OOI) and with the PAE at 5 x the MIC for p, aerugillosa (r = -
0.90, p=0.039). 
P AE determination after incubation on ice. To study the effect of free intrabacterial 
tobramycin, the PAE was determined after an ovemight incubation on ice, and the dP AE 
(8PAE = direct PAE - PAE after incubation on ice) was calculated for p, aerugillosa and 
S. aureus. The overall8PAEs (mean ± SEM) was 0,3 ± 0.5 h (p<0,0001) and 0,3 ± 0.4 h 
(p<0.0001) for p, aeruginosa and S, aureus, respectively, indicating a slight but 
significantly lower PAE when the PAE was determined after incubation on ice. 
Differentiation of the APAEs determined when the concentration was at its peak versus 
those determined when the concentrations were at 5 x the MIC and I x the MIC indicated 
that the effect of additional incubation on ice was mainly observed for the PAEs calculated 
when the concentration at 5 x the MIC (mean ± SEM 8PAE = 0.5 ± 0.5 h, for both p, 
aeruginosa and S. alll'ells). 
Regrowth of resistant subpopulations. No resistant sUbpopulations of P. aeruginosa 
were found during any of the experiments. For S. aureus all samples showed growth on 
the plates containing 0.5 and 1.0 mg tobramycin per liter. However, the samples used to 
generate control growth curves and plated on the same plates also showed the same growth 
on these plates. This would indicate that there may be a sllbpoplilatioll in the starting 
inoculum for which the MIC that is slightly higher. Another phenomenoll, seell for S. 
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Figure 1. Representative curves for a control growth (e), control regrowth (0), killing (a), and killing 
regrowth (D) of p, aerttginosa and S. al/rellS detemlined during all experiments with the pham18cokinetic 
model. For these curves the samples for PAE measurement were taken when the tobramycin concentration 5 
x the MIC, during the simulation with a half-life of 1.5 h. PAE can be determined as PAE = T - C, as 
described by Craig and Gudmundsson (4) (see text for details). 
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Figure 2. Mean ± SEM PAEs determined at concentrations of 5 x the MIC and I x the MIC for P. 
aeruginosa and for S. al/rellS, respectively, during the simulation with different half-lives (t1l2) of 
tobramycin. 
aureus only, was the growth of small colony variants. These colony types were visible 
only after incubation for 48 h at 37'C. The MIC of tobramycin for these small colonies 
using an E-test (AB-Biodisk, Solna, Sweden), reached 2 to 4 mg/I. The generation time in 
MHBs at 37'C for the small colony variants showed a range of 55.0 to 60.3 min. (n ~ 4) 
compared to a generation time of 35 min for the original test strain and for the large 
colony types after treatment (n ~ 4). The DNAs of both the large and the small colony 
types were typed by Random Amplification of Polymorphic DNA (RAPD) by to 
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previously described protocols (23), using RAPD 1, RAPD 7 and ERlC II as primers, to 
check whether the small and large colony variants were genetically identical. Since no 
variability in amplification pattems were observed genetic differences between the two 
variants were either small or absent. 
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Figure 3. Representative control growth (0), and killing (0) curves of P. aerugillosa in the in vitro model 
during a simulation of the pharmacokinetics oftobramycin in mice with renal impaimlcnt determined with a 
halfMlife of2.5h. PAE was determined as PAE = T - C - M (13), where T = the lime for the drug exposed 
bacteria to grow 1 loglo CFU, C the corresponding time for the non-exposed control, and M = the lime 
above the MIC. 
Simulation of in vivo PAE in mice with renal impairment. A representative example of 
a killing curve of P. aeruginosa, combined with its growth curve, as determined in the 
phannacokinetic model after one tohramycin dosing interval, is shown in Fig. 3. These 
curves indicate the existence of a prolonged regrowth time after the concentration has 
declined below the MIC, resulting in long P AEs. The mean PAEs of the strains 
detennined during those simulation experiments are shown in Table 1. These data were 
compared with the PAE values determined when the concentration was at its peak (20 x 
MIC) and at I x MIC, as determined during the experiments described above. This shows 
a long P AE for Pseudomonas, when simulating the in vivo circumstances, which is even 
longer than the PAE determined at 20 x MIC. For both strains the PAEs determined during 
the simulation of the in vivo situation were longer than those detennined at 1 x MIC. 
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Table 1. Comparison oftobramycin PAEs for P. aeruginosa and S, aurells detennined 
in vitro and during simulation ofin vivo PAE. 
Strain Half-life (h) PAE (h) 
20 x MIC' I x Mica Simulation of 
in vivo PAE' 
P. aeruginosa 1.5 2.0 ± 0.8 0.9 ± 0.3 6.1±0.5 
2.0 1.7 ± 0.3 0.7±0.1 5.1±0.1 
2.5 2.5± 1.0 -0.2± 0.3 5.0 ± 1.5 
S. aureus 1.5 1.7±0.1 0.9 ± 0.2 2.l± 1.0 
2.0 1.3 ± 0.3 0.3 ± 0.5 4.0 ± 1.3 
2.5 2.2±0.8 0.1 ±0.2 I.l±O.l 
a Data are means ± SEMs for two separate experiments. 
DISCUSSION 
In a previous article we described the fact that the P AE of P. aeruginosa and S. aureus 
disappeared during one interval of tobramycin dosing (5). However, the mechanism 
behind tIus phenomenon was not clear. The phenomenon of the P AE can be explained by 
several mecharlisms. One is that sublethal damage in the exposed but surviving bacteria 
needs to be repaired before regrowth can start. It could also be that sOllle free tobramycin 
remains inside the bacteria and causes growth retardation. The first explanation has been 
investigated by others (I, 9, 10), and their results indicate that DNA, RNA, and protein 
syntheses are al1 inhibited during exposure to tobramycin. For Pseudomonas DNA and 
RNA syntheses recover rapidly during the PAE phase and a large increase in DNA 
synthesis is seen shortly before logarithmic regrowth starts, In contrast, the protein 
synthesis was inhibited throughout the PAE phase and was resumed only after the bacteria 
were again in logarithmic phase of growth. The conclusions that can be drawn from these 
observations could be that sublethal damage is induced by tobramycin exposure, that the 
damage needs time to be repaired, and that this time correlates with the P AE. In an earlier 
observation Gottfredsson et al. (11) observed that tobrarnycin induced ultra-structural 
changes, such as a pattern of dense nuclear material and peripheral vacuoles, and that these 
changed during the P AE phase and disappeared at the end of the P AE phase. This also 
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indicates that during the P AE phase repair mechanisms are working in order to restore the 
normal growth rate. 
The second possibility was partly investigated in this study by determining the PAE after 
ovemight incubation on ice, thus allowing the free tobramycin inside the bacteria to 
diffuse out, where it would be eliminated by the tobramycin-acetylating enzymes (these 
enzymes also work at O°C; data not shown). OUf results indicate that free intrabacterial 
tobramycin has only a very minor effect. The largest effect of intrabacterial tobramycin 
was seen in the experimental groups with the longest exposure time at a relatively high 
tobramycin concentration (samples taken at 5 x the MIC). The PAE thus seems to be 
predominantly due to sublethal damage, reflected by inhibition of DNA, RNA and protein 
syntheses during the P AE phase, rather than due to free intrabacterial tobramycin. 
During the PAE determinations the control regrowth curves seem to have a little lag phase, 
compared to the control growth curve in the model, before exponential regrowth begins. 
This may be explained by an inoculum effect due to dilution of the control sample 
inoculum to the starting inoculum of the test strains. Furthermore, at the time that the 
control samples were taken the growth of the control was at the start of a stationary phase, 
as is indicated by the flattening of the control growth curve. Another explanation for the 
growth rate difference may be that the control growth was detennined in the in vitro 
model, in which the growth rate is slightly faster (unpublished data), while the regrowth of 
the control was determined in a tube. 
The repair processes which take place during the P AE period may well start at the time the 
tobramycin concentrations are declining toward the MIC. The PAE in vitro is normally 
determined after a short on-off exposure to the antibiotic. This fast removal corresponds to 
a very short half-life of the antibiotic, which may be too short for a repair process to have 
started. By varying the half-life of tobramycin over a range of 0.5 to 2.5 h, the time 
available for this repair process to start can be influenced. In the present study, the overall 
effect of the half-life oftobramycin on the PAE is that the PAE diminishes with increasing 
half-lives and finally disappears. TillS indicates that for short half-lives, there is 
insufficient time for tlus repair process to have an effect, so a PAE is still present at the 
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end of the dosing interval, while for longer half-lives this time for repair is prolonged, 
resulting in a disappearance of the PAE at a tobramycin half-live of 2 to 2.5 h or longer. 
The minimum half-life needed for the PAE is clearly strain dependent as would be 
expected. Stronger evidence for the existence of repair mechanisms, which are active 
during therapy and before the concentration declines below the MIC, would be the 
observation of ultrastructural changes, as mentioned earlier. For a further confirmation of 
our hypothesis concerning the repair mechanism, our experiments need to be combined 
with those of Gottfreddson (9,10, II). 
Shorter half-lives of tobramycin result in smaller Aves and a shorter T>MIC' The 
correlation seen between the increasing half-life and the decline of the PAE can thus also 
be expressed as a correlation between Ave and PA:E or T>MIC and PAR. Since only one 
dose was administrated in these experiments, it is not possible to dctcnuine the most 
important parameter for the disappearance of the PAE. Extrapolation of the data on PAE 
and the different AUCs using linear regression analysis showed that the AUC had to be 
40.4 mg.hli for the P AE to became zero for S. aureus. However linear regression showed a 
reasonable fit only for S. aureus (FO.86), so with these data no unifying AUC could be 
determined explaining the disappearance of the PAE during therapy. The same was tme 
for the T'Mle and the P AE. 
The influence of the half-life on the disappearance of the PAE seems contradictory with 
the PAE determined in vivo. Craig et a!. (3) showed in a mouse model that the PAE of 
amikacin for P. aerugillosa was prolonged when they used a half-life that was increased to 
1.5 or 2.0 h instead of the normal half-life of 18 to 32 min. In animal studies the PAE, by 
definition, is detemlined as delayed regrowth compared to the growth of a control after the 
concentration of the antibiotic falls below the MIC. Tins is precisely the difference 
between the methods for PAE determination in vivo and in vitro. In the in vitro PAE test 
the delay in regrowth is measured in antibiotic-free medium, while in vivo this delayed 
regrowth is determined at sub-MICs. This may partly explain why the PAE determined in 
vivo in mice with nomml renal clearance is longer than those measured in vitro, since this 
may be a combination of a PAE and a postantibiotic sub-MIC effect (PA-SME). 
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Increasing the half-life in mice by inducing renal impairment results even in a longer in 
vivo P AE (3). The above results (I.e., longer PAEs in mice with renal impairment) may 
thus be explained by the longer exposure of micro-organisms to sub-MICs and should 
better be described as such. By simulation of both in vivo and in vitro PAR determination 
methods in our in vitro model, the role of these sub-MICs could be studied. With 
increasing half-lives in the in vitro model, the PAE disappeared, while during simulation 
of the in vivo PAE detennination method, the P AE was still present and even longer than 
the PAE dctennined under standard in vitro circumstances. The in vivo PAE thus 
correlates with the PA-SME as described by Odenholt-Tornqvist et a!. (21). Furthermore, 
that group of investigators recently showed (17) that there is a significant difference 
between PAE and PA-SME for Streptococcus pyogenes and penicillin when 
phannacokinetics in human are simulated an in vitro model. 
Although the P AE values simulated in vivo approach the values seen in animal models, 
they are not completely equal, indicating that other enviromnental circumstances in vivo, 
such as different generation times, may also be responsible for the in vivo PAE. This 
should be investigated by different enrichments of the media in vitro that would produce a 
generation time that approaches the in vivo generation time. Until this has been 
investigated, the importance of these environmental circumstances is not clear, but the 
sub~MICs during the detenninatioll ofthe in vivo PAE seem to be of major importance. 
Another explanation for the previous findings might be the regrowth of resistant 
subpopulations. In the present study no resistant subpopulations (or small colony variants) 
were found for P. ae1'llgil1osa. Tllis may be explained by the fact that the agar plates 
containing P. aeruginosa samples were incubated overnight and not 48 h, as was done for 
S. aureus. This was done because the P. aeruginosa colonies grew too fast for them to be 
incubated longer than 24 h. For S. aureus small colony variants were isolated, and for 
these isolates the MIC was slightly increased, but the isolates were not resistant to 
tobramycin. This appearance of a less susceptible subpopulation is thus not likely to 
explain the disappearance of the P AE during the dosing interval, since these small colony 
variants show an increased generation time compared to that for the test strain; the 
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regrowth of the small colony types would thus result in a prolongation rather than in a 
disappearance of the PAE. There was no correlation between the appearance of the small 
colony variants and any of the variables during the experiments, such as the half-life, 
AVC, T'Mlc, sample time, or PAE value. The fact that we did not find small colony 
variants for P. ael'uginosa is due to technical circumstances and not in contradiction with 
earlier findings (8). 
The observations presented above indicate that the PAE of tobramycin as determined in 
vitro under standard conditions has no clinical relevance, since its supposed effect is 
vanished at the end of the dosing interval, just as it is supposed to start being important. 
The PAEs of antibiotics exceeding the dosing interval could still be of relevance. The PAE 
detennined in vivo is possibly, for the major part, a description ofa sub-MIC effect, that is 
further influenced by the environmental circumstances in vivo. Tllis in itself is clinically 
relevant, since it describes the regrowth of bacteria during therapy. The PA-SME thus 
represents only the regrowth inhibition found when the antibiotic concentration falls below 
the MIC. 
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INTRODUCTION 
The use of combinations of antimicrobial agents is common practice during clinical 
therapy. There are several reasons why combination therapy is used or should be used, but 
all have the purpose of increasing efficacy. The main arguments can, therefore, be 
summarized as follows: to (a) increase the rate and extent of bactericidal killing activity, 
(b) prevent the emergence of resistance, (c) minimize toxicity during treatment as a result 
of reduced dosage (d) enlarge the antimicrobial spectrum in critically ill patients at a time 
that the bacteriologic diagnosis is still unknown, (e) treat patients with polymicrobial 
infections, or (f) treat patients with infections due to multiresistant micro-organisms. 
Laboratory methods have been sought for that would predict the efficacy of combination 
therapy, comparable to the determination of MICs that are used for the selection of 
monotherapy, sllch as MICs or breakpoints. This is particularly important for the reasons 
mentioned above under (a) and (t) i.e., for quantitating the combined effect of agents on 
micro-organisms. The purpose of this paper is to review the role of the microbiological 
laboratory in testing antibiotic combinations and the clinical relevance of the methods 
used. 
METHODS TO TEST ANTJDIOTIC INTERACTIONS 
The susceptibility of micro-organims to antibiotics is usually expressed as a minimal 
inhibitory concentration (MIC). Further insight in the killing kinetics of an antibiotic can 
be gained from so called time-kill experiments. In both methods bacteria are exposed to 
various antibiotic concentrations and the result i.e., growth at certain concentrations is 
somehow to be interpreted in a way that predicts efficacy in vivo. The most frequently 
used laboratory tests for investigation of the interaction of two antimicrobial agents are 
checkerboard titrations, time-kill experiments, and agar diffusion tests. These will be 
reviewed below. 
Checkerboard titrations. The most frequently used method to study antibiotic 
interactions is the checkerboard titration. In this method serial dilutions of two antibiotics 
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in concentrations equal to, below and above the individual MIC of the micro-organism are 
tested. The checkerboard consists of columns in which each well contains the same 
amount of antibiotic A being diluted along the x-axis, and in rows in which each well 
contains the same amount of antibiotic B, being diluted on the y-axis (Fig. 1). The result is 
that each well contains a different combination of concentration of the two antibiotics . 
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Figure 1. In the checkerboard, serial dilutions of two drugs are combined, usually employing ranges of 
concentrations including the MICs of the drugs being tested. The concentrations of the drugs are expressed 
in mgtl. 
For each well the fractional concentrations of these drugs can be calculated (FIC ~ 
(concentration drug A / MIC A) + (concentration drug B / MIC B)) which is the Fractional 
Inhibitory Concentration (FIC) (7, 19). These FICs are calculated for all wells with the 
lowest concentrations that show no visible growth after 24 h incubation with the target 
micro-organism. The mean FIC or Fractional Inhibitory Index for the complete 
checkerboard is then calculated as the sum of these FICs divided by the total number of 
wells (FICi ~ L FIC / n). 
A combination of the drugs is defined as synergistic if the FICi ,; 0.5, as additive or 
indifferent ifO.S < FICi < 4.0, and as antagonistic ifFICi <:4.0 (1). However, there is no 
universal consensus regarding the criteria that define additivity and antagonism (20). 
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In the checkerboard, serial two-fold dilutions have been generally used. with end-points 
being inhibitory effects (21). However, some authors have recommended smaller 
concentration intervals, known as modified dilution checkerboard titrations, because such 
titrations are thought to result in greater precision (28, 31, 32). In tests using two-fold 
dilutions the precision of the test diminishes especially at higher concentrations of the 
drugs than happens in the modified dilution-system. Thus using this latter dilution scheme 
will result in more precise FICi values and consequently the modified checkerboard 
titration should predict synergism more precisely (31). However, the modified 
checkerboard titration is very laborious and has received little attention. 
There are several methods available to perform a checkerboard titration. The one most 
frequently used is the broth dilution method. This method can be applied to micro- and 
macrodilution titer plates. Much less used is the agar dilution method, in which the 
antibiotic dilutions are put in semi-solid agar bases. The advantage of this latter method is 
that a large number of strains can be tested simultaneously on single series of plates (21). 
Time-kill curves. One of the major problems of the methods described above is that 
killing kinetics arc not taken into account, i.e. the rate of killing over time during an 
exposure of a bacterial culture to an antibiotic. One of the solutions to this problem is the 
use of time-kill experiments. This method is more laborious as it depends on repeated 
sampling over 24 hours, but compared to the checkerboard titrations it results in more 
information. For example it gives insight in both the rate and extent of killing. In those 
tests synergism is generally defined as a 2 Log" smaller CFU/ml count remaining after 24 
hours exposure to the combination compared to that found after exposure to the most 
active drug alone (Fig. 2) (21). However, this definition is valid only if at least one of the 
two tested drugs produces no inhibition or killing when given alone. Thus, if both agents 
are bactericidal there is no generally accepted definition of synergy in time-kill 
experiments. Furthermore, some authors require 3 Log lO CFU/ml difference in bacterial 
activity for the combination to qualify as synergistic (44). 
Diffusion techniques. During the last decades many other tests for synergy / antagonism 
have been described in literature. Most of these tests were simplifications of the 
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established synergy tests, including diffusion around antibiotic containing discs (14, 38, 
43,38,55,60) or from antibiotic containing paper strips (2). However, none of these 
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Figure 2. Effects of combinations of antimicrobial agents as detemlined with a time-kill experiment. The 
different panels show the way synergism, indifference and antagonism may become evident during time·kill 
experiments, 
methods has not become generally accepted nor did they find their way to the routine 
laboratory. A recently described method based on the E-test seems to be a promising 
alternative (58). In fact, the E-test method is a combination of the known agar difthsion 
test (33, 49, 56, 58) and the checkerboard titration. 
E-test. E-tests are plastic strips coated with a continuous gradient of antibiotic 
concentrations on one site and a concentration scale of antimicrobial agent on the other 
side. The E-test (AB-Biodisk, Solne, Sweden) (Fig. 3) for combinations of two antibiotics 
(58) enables one to determine a value, which is comparable to the FICi in checkerboard 
titrations. Several other investigators (1O, 30, 49) have described variations on the method 
of White et aJ. (58). The advantages of lhis test are its ease of application and its high 
reproducibility (58). These two properties allow routine laboratories to test for synergy of 
combinations of antibiotics at short notice. 
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Figure 3. Schematic diagram ofthe E-Iest method to detennine synergism modified after White et a!. (58). 
EVALUATION OF ANTIBIOTIC INTERACTIONS 
One of the disadvantages of the FICi (as explained above) is that it is a calculated average 
of the results of the checkerboard titration, while actually there are arrays of data in temls 
of growth or no growth. By calculation of the FICi much infonnation is lost which could 
add to our insight in the interaction between antibiotics. This was the base for the 
development of computer programs that take all the information of the checkerboard 
titration into account. For example, the data derived from a checkerboard titration can be 
processed through a computer model that generates three-dimensional (3D) pictures of the 
interactions of the two tested drugs. Such 3~D graphing techniques and mathematical 
analysis are now becoming more widely used for the study of the effects of combination 
therapy. Greco et al (25) established the URSA (universal response surface approach), and 
Prichard and Shipman developed the MacSynergy II program, in order to analyze 
combination therapy data (48). Drusano et al. (18) used a comparable 3-D model for the 
study of combination therapy against HIV, and recently a comparable method was used to 
show synergism of oral streptogramines (RPR 106972) (17). 
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Li et al. (39) described the so-called fractional maxima! effect method (FME) as a way to 
characterize the efficacy of antibiotic combinations. Their method was based on a special 
type of time-kill experiments and data processing to obtain a graphical representation 
revealing antagonism or synergism between the tested antibiotics. The FME method was 
later used by Hyatt et al. (33), but neither study was able to indicate the value of their 
studies for the prediction of clinical outcome. Although the use of these computerized 
models provide more insight in the complexity of the interactions between antibiotics, 
none of these programs arc available in a version usable for routine laboratories and all 
need further development and validation in clinical practice. 
COMPARISON BETWEEN DIFFERENT TECHNIQUES 
Checkerboard titrations and time-kill curves. Most of the studies evaluating the use of 
in vitro methods as a predictor for the efficacy of combination therapy use only one 
method to detennine synergism. In a few studies only, it was attempted to compare both 
checkerboard titrations and time-kill tec1ll1iques (Table I). The overall correlation between 
the two tests varied between 0-100%. The wide range of these correlations is partly 
explained by the differences in definitions for synergy in both methods. In studies using a 
checkerboard titration technique the definition for synergism is a FICi < I or FICi < 0.5 
depending on the study. For a time-kill tec1ll1ique a 2 Log lO larger decrease in CFU/ml for 
the combination compared to efficacy of the most active single agent is the definition 
which is most frequently used, but a decrease of 3 Log lO is also used (44). 
Furthermore, the concentration of the antibiotics used in time-kill experiments may differ. 
For example, a combination may appear to be synergistic at a concentration of ~ x MIC 
but not at I x MIC. Also, the starting inoculum and the end-point are not always the same. 
All these differences in methodology make it very difficult to compare the results of tests 
that are based on the same principle. It is even more difficult to compare the results of two 
tests. It may be concluded that without further standardization, comparing the results 
within each method and between methods remains very difficult if not impossible. Norden 
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et a!. (46) 20 years ago concluded that the frequency of synergism varied significantly 
with the method of determination used (inhibition of bacterial growth vs. rate of killing of 
bacteria). It is unfortunate that after so many years the same conclusion is forced upon tiS, 
and that there is still no single validated method for testing the presence of synergy or 
antagonism of two antimicrobial agents used in clinical practice. 
Table 1. Correlation between results ofa checkerboard and a time·kill technique. 
Ref. Strains Antibiotics percentage agreement 
4 A. Balllllatmii levofloxacin, ofloxacin. 0% 
or ciprofloxacin + Amikacin 
16 P. aeruginosa tobra I cefta 60% 
5 S. pneumoniae cefsul/ tohra or amika 18·51 % 
58 P. aeruginosa, E. cloacae cefta I cipro or tobra 44 - 88 % 
E. coli, S. aurells cefotax I cipro or tobra 
47 P. aerl/gil/osa cefta or cefotaxim with 33 -100% 
syso, amika or genta 
44 P. aerugillosa, Enferocci azlocillin I ciproiloxacin 83-100% 
Streptococci group D 
13 P. aerllgillosa cefsulodin I amika or tobra 10-60% 
46 K. pnellllloniae cephalotin I gentamicin 22-41% 
27 P. aerugillosa, E. coli, gentamicin I cefotaxime 50-70% 
P. maltophilia, gentamicin I ceftazidime 
53 P. aeruginosa ceftazidime I netil or tobra 100% 
PHARIIIACODYNAIIIIC STUDIES 
The methods described above all show one important difficulty with respect to the 
applicability for the clinical setting i.e., they are perfomled at fixed or static antibiotic 
concentrations. In contrast, in patients the antibiotic concentrations vary greatly over time. 
Two types of experiments have tried to address this problem, i.e. in vitro phamlacokinetic 
models and animal model experiments. 
In vitro pharmacokinetic models. Several investigators have studied the efficacy of 
combination therapy in an in vitro pharmacokinetic model in which concentration profiles 
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mimicking human phannacokinetics are generated. Most of these studies were able to 
show an increased or at least equal killing efficacy of combination therapy over 
monotherapy (Table 2), Since there is no unequivocal definition of synergism in in vitro 
models the same problem arises as previously described for time-kill curves. One of the 
most frequently used definitions for synergism in a model is a 2 Log lO larger decrease in 
CFU for the combination therapy as compared to the results of monotherapy of the most 
active drug, comparable to that used for time-kill experiments. Other less frequently used 
methods are to determine the time needed to kill the bacterial culture below 10' CFU/ml 
(6) and a decrease of 3 Log1o CFU/ml of the combination therapy compared to 
monotherapy (44). Overall these phammcokinetic models yield much more infonnation 011 
the killing kinetics during antimicrobial therapy. For example K5nig et al. (37) found that 
with susceptible strains non-simultaneous administration of combination therapy was 
more efficacious than simultaneous administration. In a more recent publication Barclay et 
al. (6) show the same. In contrast Den Hollander et al. (16) show that for a P. aeruginosa 
strain that was resistant to both antibiotics there was no difference between the two modes 
of administration. Since the circumstances simulated in in vitro pharmacokinetic models 
better approach the exposure of bacteria in patients, it is likely that these models also 
better predict the activity of combination therapy in clinical practice. 
The data obtained with checkerboard titrations or conventional time-kill experiments 
showed a poor relationship with data observed in in vitro phannacokinetic models. For 
example Zinner et al. (61) found that a P. aerugillosa strain with a FIC, = 13 (being 
extremely antagonistic) for the combination of piperacillin and thienamycin was slightly 
killed by this combination in the in vitro phannacokinetic model and the combination thus 
seemed to have at least an additive effect on this strain. 
Animal models. The study of infections in experimental animals provides the opportunity 
to study the antimicrobial response in vivo. Although interactions between antibiotics can 
also be studied in in vitro pharmacokinetic models, the interactions of antimicrobial 
agents, bacteria and the host defense systems can only be investigated in animal models or 
in patients. Again the difference between in vitro synergy data and treatment outcome in 
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animal models is striking. Several review articles in the past two decades have presented 
these problems very clearly (II, 22, 24). According to Renneberg et al. (52) the difficulty 
in comparing the results of the animal studies to those of in vitro studies reflect the 
difficulties of interpreting in vitro data to response observed in clinical practice. \Vhen 
looking at the results from animal studies only, the results are favorable for combination 
therapy. For example, studies concerning experimental endocarditis show a favorable 
clinical outcome when a low dose of gentamicin is combined with penicillin (54). 
However most of these studies did not look at a correlation between experimental clinical 
outcome and in vitro synergism tests. 
Evaluation of phal'macodynamic studies. All studies on in vitro and animal models 
cited so far do not provide a firm rationale for combination therapy, nor are they able to 
predict clinical efficacy. A few investigators have tried to use pharmacokinetic and 
pharmacodynamic parameters to predict the outcome of combination therapy. Mordenti et 
al. (45) infected neutropenic rats intraperitoneally with Pseudomonas aeruginosa and 
treated them with amikacin and ticarcillin either alone or in combination. They used both 
recurrent bolus injections and continuous infusion. The test strain was synergistically 
sensitive to the combination (\4 • MIC of each dmg) of both dmgs (the method by which 
this was determined was not described in their article). It turned out that the best 
combination therapy regimen was the one where amikacin and ticarcillin concentrations 
remained continuously above % times their MICs, respectively. They concluded that 
intermittent bolus dosing tended to result in non-synergistic drug concentrations when 
concentrations feU below \4 • MIC for one or both dmgs for a part of the dosing interval. 
The greater the non-synergistic time period, the less effective the therapy became. This 
explains why for extremely sllsceptible strains the treatment regimen may not be 
important. This could also explain why other investigators (6, 26, 37) found that non-
simultaneously administration of drugs in given combination therapy was more effective 
for susceptible strains than for resistant or intermediate susceptible strains (Table 2). This 
observation may, however, not be due to synergistic killing by the two antibiotics, but 
rather be due to the fact that at least one of the antibiotics was above the MIC during the 
Table 2. Articles about combin:ltion therapy in in vitro plmnn:lCOkinetic models. 
RO=~ 
16 
12 
40 
41 
" 
" 
26 
37 
6i 
9 
Bactcrial strains Antloiotic combinations 
P. aerugJnosa Cef\:Jzidime + Tobr:unyein 
P. acruginosa 
S. cpidcnnldls 
• == 
1'. ocrogino:so 
S.auf'CUS 
P. ireroginosa 
P. ocruglnosa 
P. m:rogJnosa 
S. epiderm/dis 
P. aerugJno.<Q 
£ mil 
P. ocrogmosa 
P. acruginosQ 
Ceft:l:eidime + Anlik:lcin 
Rifampicin + Vancomycin ITeicopl:min 
Arnikacin + Vatlcomycin f Tcicopl:lllin 
Cef\:Jzidime + Gentamicin 
Gentamicin + V:mcomycin I Tcicopl.:min 
Imipenem + Amikacin 
AmiI=in ... Ceftm:idime! CdipiIne 
Aztreo= + CcfbJzidime I Cefipimc 
Amikru:in + Cd't:a.::idimc / FlucloxaciUin 
Ticarcillin + Gcntlmicin 
Gentamicin + Ampicillin 
Piperacillin + Thi=ycin I Amikacin 
Azlocillin + Ncti1micin 
Cc:ftazidimc + Nctilmicin 
Conclusions 
Combin.:rtion therapy with once <bily tobramycin was signific:mtly~. than multiple d:uly lobrnmycin dosing. 
Non-sUnulbnCOUS administration is equal to simultaneous for a resistmt str:Un. 
Killing during combination therapy is more pronounced than during monotbcl'Upy. 
Combination tbcrnpy with rifumpicin shows better killing, th.m tcicopInnin alone. 
Then:: is a good correlation between dab from the in vitro model and the tissue CllgC model in guinea pigs • 
Non-simultaneous administration showro improved cffic:.cy over simultaneous for a susceptible str::Iin. 
Combination therapy showed a bl:tter killing than mnnntherapy. 
~t:unicin:md tcicopl:min shnwed a ~cidal effect, while tcicopl:min alonc nnly sbnws a bactcrinstltic effect. 
Combinatinn therapy results in a better killing. especially if the str:Un is rcsistanttn nnc nfthe drugs. 
Combinatinns with amikacin shnw bl:tter killing than with aztrconam. 
Combinatinn therapy shnws a better kiIling against :idbcrcnt bacteria than monntherapy. 
Combinatinn thc:l'apy with flucJoxaciIlin sbows a bl:tter killing effect than with ccfl:a2jdime. 
Non-simultanCQus administratinn shnwed improved dficaey over simultaneous fnr a susceptible str.Un. 
Nnn-simultaneous administr:ltinn showed imprnved dficaey over simultaneous for a susceptible str.Un. 
Combinatinn therapy of az)ociI1in + netilmicin showed the best killing effect 
Antagonistic combinatinn nfpipcraciI1in + thicnamycin(eheekerboard titratinn. Frq=13) w:lS shnwn til, be additive 
in an in vitro pbarmacokinetie model. 
Bactericidal activity is enl=ccd during cnmbinatinn therapy, i.e. greatc:r initial killing and prevention of emergence 
nf resistance. Chcc:kcrbo:lrd titr.ltinns Wcl'<: predictive nfthc initial killing effect rnther than the final ottenl nf lolling. 
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complete treatment period. In contrast to all the studies above, Den Hollander et al (16) 
used a resistant strain of P. ael'uginosa and found that there was no difference between 
simultaneous and non-simultaneous administration. During the experiment concentrations 
for either antibiotic were below the MIC all the time. They also found that a regimen in 
which tobramycin was given once daily and ceftazidime thrice daily was the most 
effective, possibly because this regimen had the longest synergistic period (time above Y4 * 
MIC for both agents). 
A second attempt to explain the effect of synergistically acting antibiotics during treatment 
was proposed by Renneberg (SI). He developed a formula describing the in vivo drug 
interaction (IDI), which combines the biological effect (Le. extent of killing) and the time 
during which the antibiotic concentration exceeds the MIC. He then calculated synergism, 
addition, indifference and antagonism during the complete treatment period and found 
that, according to his formula, drugs may be acting synergistically during the first day of 
treatment, while tltis effect may disappear after several treatment days. This might explain 
why one large dose of an aminoglycoside at the beginning of therapy is as effective as 
continued amino glycoside dosing during all treatment days. 
Relmeberg et al. (SI), however, did not take into account that the MIC during therapy 
ntight be lowered if the antibiotics act synergistically (Y<' MIC) (4S). Thus, it is possible 
that if he had used Y< • MIC instead of the MIC the IDI would have indicated synergism 
for a longer period of time during treatment. 
Another approach was recently further studied by Den Hollander et al. (IS). They showed 
that during combination therapy the susceptibility of the test strain may be indicated by the 
MICCOMB1' which is the MIC of an antibiotic in the presence of a second antibiotic. Tltis 
MICCOMD1 is easily determined using the E-test method for combination therapy, as 
described by Wltite et a!. (S8). Using this test they found that four resistant P. aerllginosa 
strains behaved as susceptible strains as long as one of the antibiotic concentrations was 
above this MICco,mI during the time of treatment. This indicates that this test may be 
usable as predictor for susceptibility and efficacy during combination therapy. If these 
observations can be repeated, the E-test for combinations of agents could be used as a 
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single laboratory parameter similar to the MIC for monotherapy. Breakpoints for 
combination therapy will then have to be detennined on this basis. 
COMBINATION THERAPY IN CLINICAL INFECTIONS 
As stated earlier there are several reasons to use combination therapy in the clinical 
setting. During recent years most clinical studies compare the efficacy of combination 
therapy with that of mono therapy, especially when a single new dmg is promoted to be as 
efficacious as the combination of two agents used so far. Unfortunately, few studies have 
investigated the clinical outcome of combination therapy and its correlation with in vitro 
data, such as MICs and FICs of the clinical isolates. Those studies did compare in vitro 
data with clinical outcomes as discussed below. 
K1astersky et al. (35) showed that combinations of antibiotics that were synergistic in vitro 
were associated with favorable clinical outcome in 75% of cases, while infections caused 
by bacteria that showed no synergism to the combination therapy responded only in 41 % 
of cases (p<O.OI). The difference was especially striking in severe infections, i.e. those 
associated with bacteriaemia and in patients that were granulocytopenic. Young (59) 
observed from a prospective randomized study on the combinations of gentamicin + 
carbenicillin versus amikacin + carbenicillin in neutropenic patients that there was a 
positive association between in vitro synergism and favorable clinical outcome. Anderson 
(3) likewise demonstrated a significantly higher response rate in patients with Gram 
negative rod bacteremia whose infecting organisms were synergistically inhibited. 
Klastersky and Zinner (36) showed a favorable clinical response in 79% of cancer or 
neutropenic patients when treated with synergistic combinations of antibiotics against 
severe infections. When the combination of the antibiotics appeared to be nonsynergistic 
the clinical outcome was much less favorable (45%). Fainstein et al. (23) described a 
clinical trial with 253 patients and 321 febrile periods treated with ceftazidime or with 
tobramycin and ceftazidime. For all patients treated with monotherapy from which an 
infecting strain could be isolated, the strains were susceptible and showed a good clinical 
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response in 88%. For patients treated with combination therapy the clinical response was 
100%. All strains isolated were sensitive to both antibiotics. Hilf et al. (29) studied 200 
patients with Pseudomonas aeruginosa bacteremia, and could neither establish a 
correlation between the MICs and the clinical outcome, nor find a correlation between in 
vitro synergy and clinical outcome. The most striking finding was that the mortality in the 
patients receiving combination therapy was 27% compared to 47% in the group receiving 
monotherapy (p~0.023). Although combination therapy shows a favorable outcome 
compared to monotherapy there was no correlation with in vitro susceptibility data in 
terms of synergism as determined by FICs. 
CONCLUSION 
Taking together all studies presenting data on combination therapy only one firm 
conclusion can be drawn: we still know too little about the rationale behind combination 
therapy. There is still no in vitro test available that can predict the clinical outcome 
comparable to the MIC for monotherapy. Such a test is definitely needed. Based on one 
recent study (15) the E-test of White et al (58) may hold some promise for the future in 
this matter. Maybe this test will yield valid breakpoints for the use of combination therapy. 
Until then the use of combination therapy in clinical practice is justified because 
combining antibiotics may well lower mortality (29), have a more favorable clinical 
outcome especially if combinations are chosen that are synergistic in vitro. 
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ABSTRACT 
Synergism between two antibiotics is usually tested by a checkerboard titration technique, 
or by time-kill methods. Both methods have the disadvantage that synergism is determined 
at constant concentrations of the antibiotics, which do not reflect reality in vivo. In the 
present study we detennined whether synergism between tobramycin and ceftazidime can 
he found at declining concentrations below the MIC, and whether change in dosing 
sequence of the antibiotics would result in differences in killing. Three mono therapy and 
six combination therapy schedules were tested in an in vitro pharmacokinetic model, using 
a Pseudomonas aeruginosa resistant to both antibiotics. During all q8h dosing schedules 
the peak concentration (C,wJ was adjusted to the MIC for the strain of both antibiotics. 
During all monotherapy regimens bacterial growth was present, while all six combination 
therapy schedules showed significant killing. At t ~ 24 h there were no differences 
between all combination therapy schedules, but at t ~ 8 h the two combination therapy 
schedules with administration of tobramycin once daily showed a significantly faster 
killing. By using the area under the killing curve (AUKC) as a parameter for synergistic 
killing, simultaneous combination therapy starting with tobramycin once daily was 
significantly better than all other regimens. We conclude that there is synergism between 
tobramycin and ceftazidime at declining antibiotic concentrations below the MIC, 
resulting in a pronounced killing of a resistant Pseudomonas strain. Infections due to 
resistant Pseudomonas strains could possibly be treated by a synergistic combination of 
these drugs. 
INTRODUCTION 
Infections caused by Pseudomonas aeruginosa continue to pose a therapeutic dilemma 
because of the high rates of morbidity and mortality, and the possibility of drug resistance 
developing during therapy. Especially in patients with cystic fibrosis emergence of 
antibiotic resistant Pseudomonas ael'uginosa strains is observed and it is associated with 
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the frequent rcquirement for antibiotic therapy in these patients (22). One way to 
overcome tlus problem is to use combination therapy. Both in animal models (14, 15, 19, 
27) and in clinical therapy (16, 17) treatment with a combination of an aminoglycoside 
with a p-lactam has shown increased efficacy. Such combination therapy is generally used 
to increase bactericidal activity and/or the rate of killing in vivo, and to prevent the 
emergence of drug resistance. Combination therapy is also used to broaden the 
antimicrobial spectrum in critically ill patients while awaiting a bacteriologic diagnosis or 
because patients have suspected or proven polymicrobial iufcctions (8). The increased 
clinical response to combination therapy is usually explained to be due to synergism 
between the antibiotics used. Synergism of a combination of antibiotics can be expressed 
as Fractional Inhibitory Concentration indices (FICi) derived from a checkerboard titration 
(2, 6, II, 26). Another way to detect syncrgism is by performing time kill curve studies 
(11, 28). However, these methods only use constant concentrations of the antibiotics, 
wluch do not take dynamically changing concentrations into account, as seen in humans. It 
has been suggestcd that synergism should bc investigated using time kill experiments 
determined in in vitro models that can simulate human pharmacokinetics (l, 3, 31). 
The purpose of the prescnt study was twofold: (i) to determine whether synergism was 
present between tobramycin and ceftazidime against a strain of Pseudomonas aeruginosa 
that is resistant to both antibiotics, during declining antibiotic concentrations, thus 
resulting in killing at concentrations below the MIC, and (ii) whether different dosing 
regimens of the antibiotics result in differences in the rate of killing. 
MATERIALS AND METHODS 
Bacterial strain and media. The strain used for this experiment was Pseudomonas 
aeruginosa CF 133, a non-mucoid strain, isolated from sputum of a cystic fibrosis patient. 
The MIC was 16 mg/l for tobramycin and 64 mg/l for ceftazidime, as determined by 
standard broth macrodilution method in supplemented Mueller Hinton broth and by 
agardilution method on ISO sensitest agar (ISO; Oxoid, Basingstoke, Hampshire, 
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England) (24), using P. aerugillosa ATCC 27853 as a test strain. The mechanism of 
resistance for aminoglycosides was partly determined by identification of the 
. aminoglycoside modifying-enzymes as described by Van de Klundert et a!. (30). The 
mechanism of resistance for pMlactam antibiotics was detennined by semi-quantitative 
susceptibility testing, substrate analysis and iso-electric focusing of the extracted fl-
lactamase (29). Mueller-Hinton broth (Difco, Amsterdam, The Netherlands) supplemented 
with Ca" (25 mg/l) and Mg" (12.5 mgtl) (MHBs) was used in all experiments. All 
bacterial samples were plated on Tryptone Soy Agar (TSA; Oxoid, Basingstoke, 
Hampshire, England). 
Antibiotics. Tobramycin was obtained from Eli Lilly and Company (Nieuwegein, The 
Netherlands) and ceftazidime was obtained from Glaxo (Zeist, The Netherlands). Stock 
solutions were prepared according to the guidelines of the National Committee for Clinical 
Laboratory Standards (24). 
FIC indices. Fractional Inhibitory Concentration indices (FlCi) were determined by a 
modified dilution checkerboard macrotitration technique (12) with synergism defined as a 
FICi of,; 0.8 (13). When two-fold dilution series were used synergism was defined as a 
FICi,; 0.5 (28). FICs and FICi were calculated in the usual way (2, 7). 
Time-kill curves. Time-kill curves were perfonned with tobramycin and ceftazidime 
alone and in combination at concentrations of 0.125, 0.25, 0.5,1, and 2 times the MIC in 
shaking tubes containing 10 ml. For each experiment a fresh overnight culture was made 
in MHBs at 37'C, and then diluted in prewarmed MHBs and shaken for 2 h, resulting in a 
starting inoculum of approximately 5 x 10' CFU/m!. Samples of this logarithmic culture 
were diluted with prewamled antibiotic solutions containing two times the final antibiotic 
concentration, or for the control pure MHBs. Samples were taken at 0, 1, 2, 4, 6, 24 h of 
incubation. The numbers of CFU/ml were detennined after making appropriate dilutions 
in cold saline, and 0.1 ml was plated on TSA plates, and incubated overnight at 37'C. All 
time-kill curves were performed in duplicate. Synergism in time-kill methods is defined as 
a decrease " 2 log" CFU/ml in the combination regimen compared to the best 
monotherapy regimen (28). The area under the bacterial killing curve (AUKCo.24h) was 
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calculated by using the trapezoidal rule on logarithmically transfonned observed data 
points. 
In vitro pharmacokinetic model. The model used was described in detail previously 
(21). 'Briefly, a two-compartment model consisting of one central compartment and three 
peripheral compartments (disposable dialyzer units [ST23, Baxter, Utrecht, The 
Netherlands]) was used to expose the bacteria in the peripheral compartments to changing 
antibiotic concentrations, mimicking human pharmacokinetics. At t = 0 h the peripheral 
compartments were inoculated with a logarithmic culture of P. ael'lIginosa CF 133 of 
approximately 5 x 10' CFU/ml, prepared separately for each compartment as described for 
the time-kill method. Control growth curves of P. ael'lIginosa CF 133 in the in vitro model 
were determined the same way only without adding antibiotics. 
Dosing regimens. The following dosing regimens were tested over 24 h: tobramycin 
monotherapy q8h daily and once daily, ceftazidime monotherapy q8h daily, combination 
therapy oftobramycin q8h and ceftazidime q8h at indicated time intervals, t = 0,8 and 16 
hand t = 20 min, 8 h 20 min and 16 h 20 min [i.e. simultaneous administration], or t = 0, 
8, 16 hand t = 4, 12, and 20 h [i.e. non-simultaneous administration], and finally 
combination therapy of tobramycin once daily and ceftazidime q8h daily. The antibiotics 
were infused over 20 minutes, and the peak concentration was detennined at 10 minutes 
after the infusion (t = 30 min). In the q8h daily regimen the dose was chosen to obtain a 
peak concentration identical to the MIC of the strain (i.e. 16 mg/I for tobramycin and 64 
mg/I for ceftazidime). For the once-daily tobramycin regimen the dose was chosen to 
obtain a peak concentration of 32 mg/I (2 x MIC). The half-life (t,n) for both tobramycin 
and ceftazidime was adjusted to 2 hours. One-milliliter samples were taken from t = 0 h, 
every hour, and at t = 0.5, 4.5, 8.5, 12.5, 16.5, and 20.5 h. The samples were innnediately 
washed (twice) with sterile cold saline and 0.1 ml was plated on TSA plates (limit of 
detection = 10 CFU/ml). Samples were assayed for tobramycin by fluorescence 
polarization immunoassay using TDxFLx (Abbott Diagnostic Division, Amstelveen, The 
Netherlands) and for ceftazidime by high-performance liquid chromatography (HPLC) as 
described earlier (23). The lower limit of sensitivity of the assay was 0.5 mg/1. The 
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between day between sample variation was less than 7%. Control runs were performed 
regularly. 
MICs. MICs for the strains isolated at t ~ 0, 8, 16 and 24 h were determined using a 
standard agar dilution method (24), to determine development of resistance during the 
experiment. To detect more resistant mutants in the starting inoculum, a fresh logarithmic 
culture of P. aeruginosa CF 133 was plated on ISO-agar plates containing tobramycin or 
ceftazidime at a concentration of8, 16,32,64, 128, or 256 mgll and 32, 64, 128,256,512, 
or 1024 mgll, respectively. 
Initial bactericidal effect. The initial killing effect of a regimen was expressed as changes 
in 10g l0 CFU/ml at one fixed time point during an experiment, or as the time needed to 
reduce the inoculum to !OJ CFU/ml (I). 
Statistical analysis. Peak and trough concentrations, half-life of the antibiotics during the 
different experiments and the time kill curves (I.e. the difference between the IOg10 
CFUlml at t ~ 0 h and t ~ 8, and t ~ 0 and 24 h, the time to a 10' CFUlml reduction of the 
inoculum) were compared by using a two-way analysis of variance (ANOVA) and 
Tukey's test for multiple comparison of significance. For analysis of the AUKC, time kill 
curves were compared with each other using a two-way analysis of variance (ANOVA) for 
repeated measurements. Monotherapy was tested against combination therapy, 
combination therapy regimens were tested against each other, and single-dose tobramycin 
was tested against multiple-dose tobramycin. The Instat 2 computer package (9) was used 
for all statistical analysis. A p value of 0.05 two-tailed was considered significant. 
RESULTS 
Mechanism of Resistance. The P. ael'uginosa CF 133 produced aminoglycoside-
modifYing enzymes, which were identified as AAC (6') II and APH (3'), and produced a 
p-Iactamase which was identified as a stably depressed chromosomal encoded class I P-
Iactamase (4). 
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FIC indices. The FlCi of P. aerllginosa CF 133 for tobramycin and ceftazidime, 
determined using a two-fold dilution method for the checkerboard titration was 0.55, 
indicating indifference. However, if the modified macrotitration technique used (12), the 
FICi was 0.37, indicating synergism between tobramycin and ceftazidime for this strain 
(13). 
Time-kill curves. Numbers of 10gIO CFVlml of single agent exposure and combination 
agent exposure at different antibiotic concentrations at the end-point (t ~ 24 h) are shown 
in Fig. I. Combination therapy showed a significant increase in killing over monotherapy 
if the concentrations were;' Yo x MlC, but this effect was not large enough to label it 
synergism according to the definition. 
The AUKCo.24h calculated for all killing curves are shown in Table I. For each 
concentration the AUKCo_24h of the best monotherapy regimen was compared to the 
AUKCo_24h of combination therapy. All combinations at concentrations':::; 1 x MIC showed 
a significantly smaller AUKC024h than monotherapy (Table I). At 2 x MlC no significant 
difference between tobramycin monotherapy and combination therapy was found, 
probably due to the pronounced killing oftobramycin, when it is used above the MlC as in 
this experiment. 
antibiotic concentration 
Figure 1. Difference in bactericidal ell"cct after 24h exposure to tobramycin ( illID ) or cel1azidime ( .. ) 
alone and in combination ( ~ ) at a concentration range of2 x MIC to 118 x MIC. Control growth curve 
( CJ ) Data are means ± SO of two experiments oflhe CFUlml present at 24 h. 
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Ph.rmacokinetic data. The peak and trough concentrations of tobramycin and 
ceftazidime and the tIf2 obtained in the in vitro model during the different dosing regimens 
showed no significant differences. The peak concentrations were 13.8 ± 1.2 mg/I, 33.7 ± 
2.0 mg/I, and 53.1 ± 5.3 mg/I, and the trough concentrations were 1.7 ± 0.5 mg/I, 0.1 ± 0.1 
mg/I, and 5.1 ± 1.1 mg/I for tobramycin (qh8), tobramycin (q24h), and ceftazidime (q8h), 
respectively. The tin was 2.3 ± 0.2 h, which is slightly but not significantly higher than the 
intended half-life. The half-lives for both drugs were not significantly different. 
Growth curve and monotherapy. Monotherapy with tobramycin (q8h and q24h) and 
ceftazidime (q8h) showed an initial decrease in CFU/mi of this resistant strain to 
approximately 10' CFU/ml during the first hours of treatment, followed by a bacterial 
regrowth (Fig. 2a). There was no significant difference between the effect of the three 
Table 1. Bactericidal activity oftobramycin and ceftazidime given alone or in combination towards a 
tobramycin and ceftazidime resistant P. aerllginosa, expressed as the AUKCI).2~~ (± SO) determined in 
conventional time·kill experiments. 
Antibiotic concentration AUKC0-24h p-value' 
tobramycin ceftazidime combination 
monotherapy monotherapy therapy 
2xMIC 93± 5 102±2 77 ± 7 0.131 
1 xMIC 126 ±4 122 ± 3 89± 3 0.008 
lh x MIC 148 ± I 141 ± I 95± I 0.001 
Y4 x MIC 159 ± 5 149 ± 4 123 ± I 0.012 
1/8 x MIC 173±4 156 ± 1 140 ± 1 0.001 
a p-value by comparing the best single agent exposure to the combination agent exposure, 
monotherapy dosing regimens detemlined by comparing the !\!og" CFU/m! at t ~ 8 and 24 
h (Table 2). All monotherapy regimens showed a slight growth retardation compared to 
the control growth curve, 
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Combination therapy. All four combination therapies including q8h tobramycin showed 
an initial killing during the first five hours of treatment, followed by a stabilization of the 
colony counts around 10' CFU/ml (Fig. 2b + c). By comparing the 81ogiO CFU/ml at t ~ 8 
hand 24 h, no differences were found among all combination therapy regimens. However, 
the 81ogiO CFU/ml of all combination therapy regimens were significantly different from 
all monotherapy regimens. 
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Figure 2. Growth and killing curves of P. aerugillQsa CF 133 in an in vitro phamlacokinetic model during 
monotherapy with tobramycin q8h (A), q24h (V), and ceftazidime q8h (0) [a] and during combination 
therapy regimens tobramycin (q8h) at t = 0 hand ceftazidime (q8h) at t = 20 min (0), and vice versa (e) 
[b], tobramycin (q8h) at t = 0 It and ceftazidime (q8h) at t = 4 h (T), and vice versa (6.) [c], and tobramycin 
(q24h) at t =0 hand ceftazidinle (q8h) at t = 20 min (+). and vice versa (0) [d]. Data are geometric means ± 
SD of two separate experiments, perfonned in triplicate. (a) in all panels denotes the control growth curve 
of the test strain in absence of antibiotics. 
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Combination therapy regimens, including q24h tobramycin, showed a pronounced killing 
during the first three hours of treatment. When tobramycin was given before ceftazidimc 
the colony counts stabilized around 102 to 103 CFU/ml; however, ifceftazidirne was given 
as the first agent a slight bacterial regrowth was seen to 10' to 10' CFUlml (Fig. 2d). This 
difference was not significant at t ~ 24 h (p~0.47, Table 2). 
Calculating the time needed to reduce the inoculum to 10' CFUlml (Table 2) as a 
parameter for the initial killing effect, as described by Barclay et al. (I), demonstrated that 
the combination therapy regimens with tobramycin q24h had a significantly faster initial 
killing compared to all other combination therapy regimens (0.001 < P < 0.01), except for 
the q8h combination therapy regimen with ceftazidirne given at t = 0 It and tobramycin at t 
~20min. 
Synergism. Synergism was shown by a decrease :>-2 log" CFUlml compared to the best 
monotherapy regimen at t ~ 8 h only for the tobramycin q24h combination therapy 
regimens, and at t ~ 24 h for all combination therapy regimens (Table 2). 
Synergism was also detemlined by calculation of the area under the bacterial killing curve 
(AUKC). An AUKC (0 to 8 h, 0 to 16 h, and 0 to 24 h) was calculated for all dosing 
regimens. If the AUKC was significantly smaller for a combination therapy compared to 
the best mono therapy regimen, it was considered as synergism. The cumulative AUKC at t 
~ 8, 16, and 24 h showed that at t ~ 8 h both combination therapies using tobramycin once 
daily gave a significant smaller AUKC than all other regimens (p<0.001) (Fig. 3). At t ~ 
16 hand t ~ 24 h all combination therapy regimens show a significant smaller AUKC than 
all mono therapy regimens, with one combination therapy regimen being significantly 
better than all other regimens (tobramycin once daily at t = 0 h, and ceftazidime thrice 
daily at t ~ 20 min, 8 h 20 min, and 16 II 20 min (0.0001 < P < 0.01)). 
Emergence of resistance. The MICs of the bacteria isolated during combination therapy 
regimens at t = 8, 16, and 24 h increased about 4 times for tobramycin, but remained 64 
mg/I for ceftazidime. During monotllerapy the MICs of the bacteria increased about four 
times for tobramycin and ceftazidime. No statistical difference in MIC rise was found 
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between the dosing regimens. No resistant mutants could be detected in the logarithmic 
culture of the starting inoculum as used in all experiments. 
Table 2. Bactcricidal activity oflobramycin and ceftazidime given alone or In combination for a lobranlycin and ceftazidime resistant 
strain of P. aeTllgil1tJsa, in an in vitro pharmacokinelic model. 
Dosing regimen 
1=8h 
tobramycin q8h ·1.2 ± 0.1 
tobramycin q24h .1.1 ± 0.1 
ceftazidime q8h -0.8 ± 0_1 
lobramycin (q8h) at t = 0 h I cefiazidime (q8h) at 1=20 min -2.1 ± 0.1 
ceftazidime (qah) al t = Oh/lobramycin (qah) al 1=20 min ·2.1 ± 0.5 
lobranlycin (qah) al 1 = 0 h I ceftazidime (qah) at t = 4 h -2.1 ± 0.1 
ceftazidime (qah) at t = 0 h I tobramycin (qah) at t = 4 h -2.6 ± 0.2 
tobramycin (q24h) al t= 0 h I ceftazidime (qah) at I =20 min -3.9 ± o.ab 
tobramycin (q24h) at t=20 mini ceftazidime {qah} at t=Oh -3.3 ± 0.3h 
a: data are means ± SD oftwo separate experiments, performed In triplkale. 
A loglo CFUlml' 
t=24h 
1.4 ±O.J 
2.3 ± 0.4 
1.4 ± 0.3 
-2.9 ± 0.8b 
-1.3 ± I.Ob 
-1.2 ± 0.3b 
-2.6 ± O.3b 
-2.6 ± I.3h 
-2.0 ± O.3b 
b: decrease in Aiog10 CFU/mi > 2 loglo, compared to the best monotherapy regimen. 
DISCUSSION 
time to rcdllce 
the inocllillm 
(SxIOSCFUfml) 
10< JOl CFU/mt 
(h) 
9.6 ± 0.4 
4.8 ± 0.2 
8.3 ± O.S 
9.9 ± 4.1 
2.2 ± 0.6 
1.1 ± 0.1 
The main purpose of tlus study was to determine whether a combination of tobramycin 
and ceftazidime. with peak concentrations in the range of the MIC and at declining 
concentrations over time. resulted in synergism, This means that the concentration was 
below the MIC for both agents during the complete experiment. When determining 
synergism. at least one of the dntgs should have a concentration. which does not affect the 
bacterial growth (8). The only experiment where the peak concentration exceeded the MIC 
was when tobramycin was given once daily. This protocol thus provided a good 
circumstance to demonstrate synergism. If killing was observed this can only be explained 
as being due to synergism. because at concentrations below the MIC growth can be 
expected when only mono therapy is given. The results indicate that synergism is present at 
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24 h for all tested combination regimens of tobramycin and cefiazidime, as shown by a 
decrease :20210g1o CFU/ml compared to all monotherapy regimens (Table 2). While growth 
occurred during all mono therapy experiments (Fig. 2a), the final CFU/ml in combination 
therapy always was below the starting inoculum. 
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Figure 3, Bactericidal effect of tobramycin or ceftazidime alone or in combination expressed as the 
cumulative area under the bacterial killing curve (AUKC), Lines represent lobramycin q8h alone (T). 
tobramycin q24h alone (.t..), and ceftazidime q8h alone (II), combination therapies tobramycin (q8h) at t = 0 
hand ceftazidime (q8h) at t = 20 min (+), and vice versa (D), tobramycin (q8h) at t = 0 hand ceftazidime 
(q8h) at t = 4 h (e), and vice versa (A), tobramycin (q24h) at t = 0 hand ceftazidime (q8b) at t = 20 min 
('7), and vice versa (¢). Data are means ± SD oftwo separate experiments perfomled in triplicate. 
The choice of combinations of antimicrobial agents in therapy is often based on the MIC, 
and sometimes on a possible synergism demonstrated by determination of the FICi in a 
standard checkerboard titration, or by time kill curves. The FICi of the Pseudomonas 
strain used in the experiments was 0.55 when using a two~fold dilution checkerboard 
titration method, indicating indifference between tobramycin and ceftazidime. However 
when using the modified dilution checkerboard titration (12), the FICi was 0.37, indicating 
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a high degree of synergism between tobramycin and ceftazidime. This confirms the 
observations of Horrevorts et al. (12, 13), that the FICi detennined by a modified 
checkerboard titration is a more sensitive teclmique for detecting synergism, due to the use 
of smaller intervals between the dilution steps. Unfortunately, studies show discordance 
between the results of checkerboard titrations and time-kill curve methods (25), between 
FICi and in vitro model studies (20, 32) and between FICi and clinical outcome (5, 26). 
Possibly, the simulation of declining antibiotic concentrations as can be produced in in 
vitro pharmacokinetic models is a better method to study synergism. Observations from 
these models may correlate better with clinical outcome since they are a better simulation 
of situations in patients. 
In time kill curves, synergism is always detennined at one time-point only (usually t ~ 24 
h), while synergism between the antibiotics is present during the complete experiment, and 
thus at each time-point. To take these dynamics into account more time points should be 
taken for the calculation of synergism. When using the AUKCo_24h as a parameter for the 
killing effect, all time-points during the experiments are used. Thus. the AUKCo.24h may be 
a better parameter of synergism. This method can be used for both conventional time-kill 
curves and for time-kill curves determined in in vitro models. By defining synergism as a 
significantly smaller AUKCo.24h of the combination therapy compared to the best 
monotherapy regimen, all combination therapy regimens showed synergism. However, by 
using the significant differences in AUKCo_24h only, one does not differentiate between 
synergism and additivity (or indifference). But it is questionable if such differentiation is 
clinically relevant. When combination therapy results in a significantly increased killing 
compared to monotherapy, combination therapy could be justified, even if there is only 
additivity. In clinical practice knowledge about killing during the complete time period of 
treatment may well be more important, than just at a single time point (t ~ 24 h). 
The significantly faster initial killing as seen in the combination regimens with tobramycin 
once daily can be explained by a fast initial killing of the bacteria susceptible to 
tobramycin since in this case the concentration remained above the MIC for about two 
hours. But this fast initial killing cannot be fully explained by this high peak 
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concentration, since it was not seen in the tobramycin once daily monotherapy regimen. 
Thus this fast initial killing has to be at least in part a result of the synergism of the 
combined agents. 
During all combination therapy regimens only on emergence in resistance for tobramycin 
was shown. The MlCs for ceftazidime did not change during combination therapy. During 
monotherapy however, the MICs for both tobramycin and ceftazidime increased about 
four times. In the starting inoculum no resistant mutants could he detected by plating on an 
antibiotic containing agar. This indicates that combination therapy may prevent emergence 
in resistance. 
Barelay et 01. (I) described a study investigating simultaneous and nonsimultaneous 
infusions of gentamicin and ceftazidime against three susceptible P. aeruginosa strains in 
an in vitro pharmacokinetic dilution model. Several time points were tested for infusion; 
however, only one injection of the antibiotics was used in those experiments. They 
concluded that the nonsimultaneous administration produced greater overall killing and 
delay in bacterial regrowth. Konig et a!. (18) investigated the dosing regimen of 
gentamicin and ampicillin against E. coli, and later the same group published the 
combination of gentamicin and ticarcillin against P. aeruginosa (10). Both shldies showed 
a greater overall bacterial killing and delay in bacterial regrowth in using nonsimultaneous 
administration given 4 hours apart. Our study could, however, not confirm this, possibly 
due to the fact that we used a resistant strain. 
Some reservations should be made concerning the fact that only one strain was tested with 
one specific mechanism of resistance. It may be possible that the conclusions based on the 
data for the tested strain will he different for strains with other mechanisms of resistance. 
At present, this limits the ability to generalize the conclusions to other strains. 
In conclusion, this study indicates that infections due to a resistant Pseudomonas strain, 
such as frequently occur in patients with cystic fibrosis, possibly can be treated with a 
synergistic combination of the antibiotics to each of which the strain is resistant. With a p-
lactam-plus- aminoglycoside combination, the best effect is possibly produced if once 
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daily doses of the amino glycoside are combined with mUltiple daily doses of the p-Iactam, 
since this may result in the fastest initial killing rates and in the smallest AUKCo.2~b' 
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ABSTRACT 
Combination therapy with antimicrobial agents can be used against bacteria that have 
reduced susceptibility for single agents. We studied various tobramycin and ceftazidime 
dosing regimens against four resistant Pseudomonas ael'uginosa strains in an in vitro 
pharmacokinetic model to determine the usability of combination therapy for the treatment 
of infections due to resistant bacterial strains. For the selection of an optimal dosing 
regimen it is necessary to determine which phannacodynamic parameter best predicts 
efficacy during combination therapy and to find a simple method for susceptibility testing. 
An easy-ta-use, previously described E-test method was evaluated as susceptibility test for 
combination therapy. That test resulted in a MICcoM.J, which is the MIC of, for example, 
tobramycin in the presence of ceftazidime. By dividing the tobramycin and ceftazidime 
concentration by the MICco~ml at each time-point during the dosing interval, fractional 
inhibitory concentration (FIC) curves were constructed, and from these curves new 
pharmacodynamic parameters for combination therapy were calculated (Le., AUCCOMBh 
ChtAX.COMBh T>MfC.COMBh and T>FICh where AUCCO:-'ffiI and CMAX.COMBI and T>Flci are the 
area under the FICcoMBI curve, the peak concentration of FICcoMBh the time that the 
concentration is above the M1CcmlBJ, and the time above the FIC index, respectively). By 
stepwise multilinear regression analysis, the phanncodynamic parameter T >FICi proved to 
be the best predictor for therapeutic efficacy during combination therapy with tobramycin 
and ceftazidime (R2 ~ 0.6821; P < 0.01). We conclude that for combination therapy with 
tobramycin and ceftazidime the T >FICi is best predictive of efficacy and that the E-test for 
susceptibility testing of combination therapy gives promising results. These new 
pharmacodynamic parameters for combination therapy promise to provide better insight 
into the rationale behind combination therapy. 
INTRODUCTION 
In the last decade three important phannacodynamic parameters which correlate well with 
therapeutic efficacy in in vitro as well as in animal models have been described. These 
parameters differentiate between groups of antimicrobial agents with diverse mechanisms 
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of action. For instance, the efficacies of p-lactam antibiotics and erythromycin correlate 
best with the time that the levels in serum exceed the MIC (T>MIc), while for 
aminoglycosides the area under the concentration-time curve (AUC) best predict 
therapeutic efficacy (32). Furthermore, aminoglycosides display concentration-dependent 
killing in vitro (9, 31) and in vivo (16), indicating the importance of the third 
phannacokinetic parameter, i.e., the peak concentration (CMAX). On the basis of these 
observations new dosing regimens of these antimicrobial agents are now being used, 
including amino glycoside dosing regimens that were changed from thrice daily to once 
daily (22, 28). 
However, all these phannacodynamic studies used single agents and pharmacodynamic 
parameters of combination therapy are still lacking. Parameters which have been used to 
show interactions during combination therapy are the fractional inhibitory concentration 
(FIC) indices (FICis), derived from checkerboard titrations (2, 3, 6, II, 14, IS, 24). 
Alternatively, a significant change in the killing rates in time-kill experiments has been 
used (7, 13,27). Recently, a computer model, the MacSynergy program, has been used to 
indicate synergism (8). This method provides us with a rating of synergism expressed as 
maximum effect of the dmg combination. Although tlus method is much more accurate in 
predicting the synergistic effect of two dmgs, it does not indicate the phannacodynamic 
parameters, which predict efficacy. 
Unfortunately, the results of the various studies are discordant with the results of time-kill 
experiments, and clinical outcome (5, 23, 24). In spite of the numerous studies evaluating 
combination therapy, no pharmacodynamic parameters that can accurately predict the 
therapeutic efficacy of combination therapy have been found. One of the most important 
reasons is that all methods described above were based on efficacy at static drug 
concentrations, while in vivo the concentrations decline over time. 
The purpose of the present study was to search for a phannacodynamic parameter that 
may predict therapeutic efficacy of combination therapy. To tills purpose, several dosing 
tobramycin and ceftazidime regimens were simulated in an in vitro pharmacokinetic 
model to study their effect on resistant Pseudomonas aerugillosa strains. A simplified 
version of the checkerboard titration, i.e., an E-test for combination therapy (33), was also 
included. 
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MATERIALS AND METHODS 
Theoretical approach. To obtain pharmacodynamic parameters for combination therapy 
that are comparable to the AVe, CMAX, and T>MTC for monotherapy, it is not possible to 
simply add the values of the pharmacodynamic parameters for the different antibiotics. 
We therefore introduce here new pharmacodynamic parameters for combination therapy, 
i.e., the AUCCOMBJ. Cl\tAX.CO;\tBh Tz..UC.COMBh and T>FlCi (the area under the FICcOMBI curve, 
the peak concentration of FICcm,mh the time that the concentration is above the 
M1CcoMBh and the time above the FIC index, respectively) which are based on FIC curves 
and which are explained below. These curves were calculated as follows. The FIC used in 
the checkerboard titration to calculate the FICi is defined as the concentration of antibiotic 
Yl (in the presence of drug Y2) in a well (Cw) divided by the MIC of that drug for the 
strain (2, 3, 10) and is expressed as: 
FICy Cw I MIC (equation I) 
The FICi is then calculated as: 
I (FICy, + FICY1) I n (equation 2) 
where YI and Y2 are the two antibiotics, respectively, and n is the number of wells used 
to calculate the sum of the FICs. 
However, in checkerboard titrations the concentrations of the antibiotics are constant in 
each well. During the dosing regimens in the in vitro model these concentrations change 
over time during the dosing interval. Therefore, we simulated the concentration-time 
curves for the individual dmgs. At time intervals of 0.1 h a FIC at time I (FIC,) was 
calculated for the concentration at that time (C,), by equation I and was comparable to the 
checkerboard titration as: 
FIC, ~ C,/MIC (equation 3) 
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resulting in a FIe curve over time. 
However, equation 3 uses the MIC during exposure to a single agent. During combination 
therapy it is likely that the MIC of each drug changes in the presence of the other drug, 
i.e., the MIC decreases if the drugs are acting synergistically. A recently described method 
(33) for susceptibility testing during combination therapy is based on the E-test and has 
provided us with a new method of determining the MIC of tobramycin in the presence of 
ceflazidime (and vice versa), which is further called the MICcoMBh and which could be 
used as a parameter for describing the susceptibility of a strain during combination 
therapy. To obtain FIC curves for combination therapy, the concentrations at each time 
point were divided by the MICcOMDI rather than the MIC, and these are expressed as: 
FIC'.COMDI ~ C,/MICcOMBI (equation 4) 
The FICco'ffil curve was then calculated by adding the FIC of tobramycin and the FIC of 
ceftazidime at the same time point in the concentration~time curves, expressed as: 
FICcm,ml = FICt, lobra + FICt,cefta (equation 5) 
Where FIC1, lobra and FICt• cefta are FICts for tobramycin and ceftazidime, respectively, 
resulting in FICcOMBI curves against time. From these FICcm,ml curves the new 
pharmacodynamic parameters AUCCOMBb Cr-,lAX.co;o..rnh and T>Flci were calculated. The 
T >Mlc.co~ml is the time that the antibiotics of one or both of the antibiotics is above the 
MICcmml. The Time above the MICcoMBI (T >MIC-COMBI) was calculated from the 
concentration-time curves for the different antibiotics by the same method as normally 
used to calculate the time above the MIC, but for the T >MIC-COMBI the MICcmml was used. 
Bacterial strains, antibiotics and media. Four non~mucoid Pseudomonas ael'ugillosa 
strains were isolated from sputa of cystic fibrosis patients (CF 133,5706,5846, and 5879, 
respectively) were used for this study. The MICs of tobramycin (Eli Lilly and Company, 
Nieuwegein, The Netherlands) and ceftazidime (Glaxo, Zeist, The Netherlands) were 
determined by a standard macrodilution method (21) in Mueller-Hinton broth (Difco, 
Amsterdam, The Netherlands) supplemented with Ca'+ (25mg/l) and Mg'+ (12.5 mg/I) 
(MHBs), as well as by the E-test teclmique (AB-Biodisk, Solna, Sweden) with Mueller-
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Hinton agar (Difco) supplemented with Ca'+ (25 mg/I) and Mg'+ (12.5 mg/I). All strains 
were resistant or intennediately susceptible to hoth tobramycin and ceftazidime. All 
samples used for determination of CFU counts were plated onto Trypticase Soy agar 
(TSA, Oxoid, Basingstoke, Hampshire, England). The mechanism of resistance for 
aminoglycosides was determined as described by Van de Klunder! et a!. (29) by 
identification of the amino glycoside-modifying enzymes involved. The mechanism of 
resistance for p-lactam antibiotics was determined by semi-quantitative susceptibility 
testing, substrate analysis and iso-electric focusing of the extracted p-Iactamase (30). 
FIC indices. FlCis were determined both by a modified macrodilution checkerboard 
macrotitration technique (14), and by an E-test technique (33) (Fig. I). The FlCs and 
FlCis were calculated as usual (2, 10). Synergism for the modified macrodilution 
checkerboard was defined as FICi of ';0.8 and indifference was defined as a FlCi between 
0.8 and 4.0 (15). For the E-test method synergism was defined as FlCi of ,;0.5 and 
indifference was defmed as a FlCi of between ;'0.5 and ,;4.0 comparable to the 
definitions used for twofold dilution checkerboard titrations (27). 
High concen!1atioll 
High concentration .--:::---1--'111''----:---:--, Low concentration 
MIC of A alone 
low concentration 
MICofAandB 
In combination 
Figure I. Schematic diagram of the E-test combination therapy susceptibility test as described by White et 
al. (33). 
Pharmacodynamics in Combination Therapy 119 
In vitro pharmacokinetic model. The phannacokinetic model used in tIus study was 
previously described in detail (20). Briefly, a two compartment model consisting of one 
central compartment and four peripheral compartments (disposable dialyzer units, model 
8T23; Baxter, Utrecht, The Netherlands) was used to expose the bacteria in the peripheral 
compartments to changing antibiotic concentrations that mimic pharmacokinetics in 
humans. At time zero the peripheral compartments were inoculated with a logarithmic-
phase culture of P. aerugillosa of approximately 5 x 10' CFUlml, with a different strain 
used in each peripheral compartment. Control growth in the model was determined the 
same way but without addition of antibiotics. 
Dosing regimens. Fourteen different dosing regimens were applied, with peak 
concentrations of 32, 16, 8, and 4 mg/I for tobramycin and 128, 64, and 32 mg/I for 
ceftazidime. The drugs were given simultaneously (Le., tobramycin at time zero followed 
by ceftazidime at 20 min, or vice versa), or nonsimultaneously (i.e., tobramycin at time 
zero and ceftazidime at 4 h, or vice versa). During the simultaneous regimens tohramycin 
was given thrice daily or once daily. The half-lives (tll2) of both tobramycin and 
ceftazidime was adjusted to 2 h. Samples were taken at 0, 0.5, 1,2,3,4,5,6,8,9, 12, 16, 
and 24 h. The samples were immediately washed (twice) with cold phosphate-buffered 
saline, and O.I-ml samples were plated on T8A plates (limit of detection, 10 CFUlml). 
Samples were assayed for tobramycin by a fluorescence polarization immunoassay using 
TDxFLx (Abbott Diagnostic Division, Amstelveen, The Netherlands), and for ceftazidime 
by high-performance liquid chromatography as described earlier (19). The lower limits of 
sensitivity of both assays was 0.5 mg/1. The between-day. between-sample variation was 
less than 7%. 
Data analysis. The pharmacodynamic parameters AVC. CMAX, and T >MIC, for the 
individual drugs were calculated from simulated concentration-time curves by the 
equation for an open-compartment model after extravascular administration (25). The area 
under the killing curve from time zero to 24 h (AUKCo.24h) was calculated by using the 
trapezoidal rule on logarithmically transformed, experimentally obtained data points. 
Statistical analysis. Peak and trough concentrations and half-lives of the antibiotics 
during the different experiments were compared by using a two-way analysis of variance 
and Tukey's test for multiple comparison of significance with the lnstat 2 computer 
package (II). A p value ';0.05 (two tailed) was considered significant. 
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The correlation between the four pharmacodynamic parameters (AUCCOMBI• CMAX-COMOb 
LMlC-COMUh and LFIC') and efficacy (Le., change in CFU per milliliter (ACFU/ml) ~ 10gIO 
CFU/ml at t~24 h - 10gIO CFU/ml at time zero or AUKCo.24h), were calculated using a 
stepwise multilinear regression analysis with the SAS computer package (26). The F-test 
was used to choose the best model. 
RESULTS 
MICs and FICs. The MICs and the MICCOMBlS of tobramycin and ceftazidime for the 
four strains were determined by the E-test method are presented in Table I. Also presented 
in Table 1 are the FICis determined by the E-test and a modified macrodilution 
checkerboard titration. The MICs determined by a macrodilution standard assay were not 
significantly different from those detennined by E-test (data not shown). The calculated 
values of the FICis obtained by using macrodilution MICs obtained by the macrodilution 
assay differed somewhat from those obtained by the E-test, but for all four strains the two 
calculations resulted in to the same conclusion, i.e., that there is synergism or indifference. 
Table 1. Analysis of susceptibility tests showing synergy between tobramycin and ceftazidime against four 
P. aerugil10sa strains. 
MIC (mgll)' MICcmmJ (mglll F1C{ 
Strain 
tobra "ft, tobra cefta E·test macrodilution 
CF 133 J2 64 6 16 0.44 0.37 
CF 5706 128 16 J2 6 0.63 0.68 
CF 5846 12 512 6 128 0.75 0.67 
CF 5879 16 512 1.5 8 0.10 0.39 
a Determined by E-test. 
b Determined by combination E-test. 
e Calculated, see Materials and Methods, 
Mechanism of resistance. All four strains produced a p-Iactarnase which was identified 
as a stably depressed, chromosomally encoded class I p-Iactamase (4). The mechanism of 
resistance for tobramycin was due to the production of several aminoglycoside modifying 
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enzymes, which were identified as AAC (6')-11 and APH (3') for strain CF 133 and CF 
5706, APH (3') for strain CF 5846, and ANT (2") and APH (3') for CF 5879. 
Pharmacokinetics and Pharmacodynamics of combination therapy. The peak and 
trough concentrations and the half-lives did not differ significantly between the 
experiments and were comparable to the values targeted for these experiments. On the 
basis of these data, the concentration-time curves and the FICcOMBI curves were simulated. 
An example of a simulation of the concentration-time curves for tobramycin and 
ceftazidime during a nonsimultaneous dosing regimen and the calculated FICcoMBI curve 
for this particular regimen are presented in Fig. 2. TIllS combination therapy regimen 
results in FICcOMBI curves with values that cycle between 0.1 and 1.1 from 0 to 24 h. 
The correlation between the values of the phamlacodynamic parameters (AUCCOMBl, 
CMAX-COMBh T>FICb and T>MIC-COMBI) for all dosing regimens and the AloglO CFU/ml, are 
presented in Fig. 3. The T>FICi and the T>MIC-C011BI showed a linear relation with efficacy, 
and AUCCOMBI and CMAX-COMBI showed a log-linear relation with efficacy. The correlation 
between the four phannacodynamic parameters and the AUKCo_24h was less than between 
the four phannacodynamic parameters and the "'loglO CFU/ml over 24 h but showed the 
same trend for importance of the parameters (Table 2). The most important parameter 
predicting efficacy was LPICi as shown by the coefficient of determination (R') for all four 
strains and all regimens together, which was 0.6821. For strain CF 133 enough data were 
available to calculate the R' for the individual parameters. The R' values for this 
individual strain showed the same trend as for the four strains but were higher. For the 
most important parameter, T>F1ci, R' was 0.7604 (data not shown in Table 2). 
Table 2. Correlation between pharmacodynamic parameters and efficacy during combination therapy. 
Phannaoodynamlc Range of 
parameter values tested 
AUCOOMBI (h) 0-230 
CMA-'(.('OMlll 0-25.5 
T>}OC-WMIIl (h) 0-23.9 
Loo(h) 0-24 
• AUKCo-lI~ calculated as IOgl~ CFU.hlml. 
coefficient of determination (Rl) 
Alog1() CFUlmL at 24 h 
0.5233 
0.5652 
0.5344 
0.6821 
AUKc"m' 
0.3070 
03929 
0.3520 
0.5350 
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Figure 2. Representative conccntration·versus-time curves for ceftazidime (top) and tobramycin (middle), 
and the corresponding FICcOMBI-versus-time curve (bottom), during one combination therapy regimen. In 
this case the FICcOMBI curve, the MIC and the MICcoMBI are based on data for Pseudomonas aeruginosa CF 
133. Breakpoints arc according to NeeLS guidelines (19). 
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Figure 3. Correlation between phannacodynamic parameters for combination therapy and efficacy, 
expressed as .6.CFU/ml. 
DISCUSSION 
We studied various dosing regimens for combination therapy to determine whether 
combination therapy may be efficacious against resistant strains, and if so, to determine 
what pharmacodynamic parame1er(s) may best predict efficacy. Recently, we showed that 
combination therapy of tobramycin and ceftazidime was effective against a Pseudomonas 
ae/'llgillosa strain resistant to both drugs (7). The use of combination therapy that has a 
synergistic or additive effect may thus be a strategy for treating patients with infections 
due to multiply resistant strains. For the selection of the optimal dosing regimens for 
124 Chapter 9 
combination therapy two important factors should be known. First, a method which 
indicates the susceptibility of a bacterial strain during combination therapy is needed, and 
second, the pharmacodynamic parameter(s) that predicts efficacy should be elucidated. In 
this study of combination therapy of tobramycin with ceftazidime against resistant 
Pseudomonas strains, both objectives were goals. 
Recently, White et al. (33) developed an easy method of calculating the FICi from MIC 
data obtained with E-test strips. By their method, it is possible to detennine the MIC of 
tohramycin in the presence of ceftazidime and vice versa, thus providing a MICcoMBI of 
each drug. If a combination of drugs with synergistic or additive activity is used, a 
decrease in MIC of the combination compared to the MIC of the individual dmg is seen. 
To evaluate whether a strain was susceptible to tobramycin during combination therapy, 
the breakpoints for the individual drugs were used initially. Thus it was shown that P. 
aeruginosa CF 133, which was resistant for both tobramycin and ceftazidime according to 
the National Connnittee for Clinical Laboratory Standards (NCCLS) (21) appears to be 
susceptible to both antibiotics if they are used in combination (Le.) the MICcoMm was 
below the NCCLS breakpoint for monotherapy). This observation explains our earlier 
finding that this strain was killed during an in vitro simulation of combination therapy 
regimens conunonly used in cystic fibrosis patients suffering from P. ael'uginosa 
infections of the lung (7). For all four strains the MICco""ls were lower than the MICs 
(Table 1), and as was to be expected, all strains were killed in the in vitro pharmacokinetic 
model if combination therapy of tobramycin with ceftazidime was simulated. Indeed, 
using the various regimens, all strains were killed to some extent as measured by the 
lIloglO CFU/ml at 24 h. Compared to the NCCLS susceptibility breakpoints of tobramycin 
or ceftazidime (21), the MICCOMBIS of two strains (strains CF 133 and CF 5879) were 
below these breakpoints for both antibiotics, while for the two other strains one of either 
of the two MICcOMDIs was below the NCCLS breakpoint (Table 1). Tltis may explain why 
all four strains behaved as if they were susceptible during time-kill experiments in the 
pharmacokinetic model, since they are susceptible to at least one of the two antibiotics. 
Thus, it may be concluded that if the MICcOMDI of at least one of the drugs used during 
combination therapy is below the NeCLS breakpoint, it is to be expected that the micro-
organism will be killed during combination therapy. Since no susceptibility breakpoints 
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for combination therapy have been published, the data presented in this study suggest that 
if the MICCOMBI is lower than the NCCLS breakpoints (based on monotherapy regimens), 
the MICcOMBJ is a reasonable predictor of susceptibility during combination therapy. 
These observations only indicate that at least for the four strains used, the susceptibility 
during combination therapy can be predicted by the E-test method (33). However, this is 
only based on the results for four strains, and it is therefore too preliminary to introduce 
this test as a new standard for testing susceptibility to combination therapy. It only 
suggests a new line of research that seems worthy of examination. Further in vitro and in 
vivo experiments are needed to further confinn this or to develop new breakpoints for 
combination therapy. 
A similar relation between in vitro data and in vivo susceptibility of a resistant strain was 
shown by Mordenti et al. (18). They compared data derived from in vitro standard time-
kill experiments and similar tests in an animal model combining amikacin with ticarciHin. 
They showed that the lowest concentration of the drugs that was still synergistic in 
standard time-kill experiments predicted whether a resistant strain would be susceptible 
during combination therapy. However. the use of time-kill experiments is far more 
laborious than the E-test method recently described by White et al. (33). 
To study the pharmacodynamic principles of combination therapy in a similar way to that 
used for monotherapy (31,32), new parameters are needed. Such new parameters 
(AUCCOMBh C~1AX.COMB" and T>Flci) obtained with the use of FIC curves and a fourth 
parameter (Le., T>MIc.cm..mI) that could be estimated from the concentration-time curves 
were proposed in this report. A stepwise linear regression analysis of these four new 
phannacodynamic parameters for combination therapy revealed that the T >FlCi was the 
most important parameter that predicts the efficacy (p < 0.01) of tobramycin and 
ceftazidime combinations against P. aeruginosa. For all four strains together this 
parameter showed a reasonable correlation with the lIiog lO CFU/ml at 24 h (R' ~ 0.6821); 
an even better correlation was found for strain CF 133 alone (R' ~ 0.7604). The fact that 
the T >FICi is important may explain why the use of Ilonsimultaneous dosing regimens will 
result in larger killing than that from simultaneous dosing of these agents (1, 12, 17), since 
the non-simultaneous regimens provide longer T>FlCiS compared to those provided by 
simultaneous dosing regimens. However, due to variability in the data these correlations 
may seem over interpreted, but the multilinear regression analysis and the statistical tests 
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show significant correlations. Even though there is a variability in the data, the 
correlations between the four pharmacodynamic parameters and efficacy suggests that all 
parameters are linked with efficacy and further research along these lines certainly is 
needed to reveal the right correlations for all kinds of combination therapy. 
In conclusion, we described a simple method of detennining the susceptibility of a strain 
during combination therapy, and propose new pharmacodynamic parameters (AUCCOMBh 
CMAX.COMBh T>FICi. T>MIC.COMBJ) which predict the efficacy of the combination therapy; of 
these, the T >FlCi seems to be correlated best with efficacy of combination therapy with 
tobramycin and ceftazidime. The efficacies of other drug combinations may well be 
predicted by other pharmacodynamic parameters. Such knowledge would provide a 
rationale for dosing regimens with combination therapy and may provide us with optimal 
dosing regimens for treatment of patients with infections due to multiply resistant bacterial 
strains. 
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ADDENDUM 
Stepwise description of the dynamic FIC curves is as follows: 
I. Determine the MICcoMBI for each drug and strain using the method of White et a!. 
(33). 
2. Calculate the concentration-time profile for the drug regimen, comparable to Fig. 2A 
andB. 
3. Divide for each time point the actual drug concentration by the MICcoM", of that drug. 
Add the two FICs at that time point and plot those against time. This results in the 
dynamic FICcoMBI profile shown in Fig. 2C. 
4. Use tlus FICcm.ml-versus-time profile to calculate three new pharmacodynamic 
parameters: AUCCOMDh C~1AX·cO;\mh T>FICi. 
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5. Calculate the T>MIC.COMBh which is the time during which at least one of the dmg 
concentrations is above the MICcOMDT from the two drug concentration-versus-time 
profiles (Fig. 2A and Bl. 
6. The therapeutic effect can be expressed as the i'lLog CFU/ml at 24 h and as the 
AUKCo.24h. 
7. Try to find a correlation between the pharmacodynamic parameters for combination 
therapy and the therapeutic effect. 
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SUMMARY 
The clinical importance of the pharmacodynamics of the various antimicrobial agents has 
become evident in the last decade. As an example we now know that the efficacy of p-
lactam antibiotics is primarily dependent on the time of their concentration at the site of 
the infection is above the MIC of the infecting micro-organism, while for aminoglycosides 
and qllinolones it is the area under the concentration time curve (AUC) that is the most 
important determinant of efficacy. Based on this knowledge dosing regimens have been 
adjusted. The pharmacodynamic parameters of antimicrobial agents can be investigated in 
experimental models of infection in animals and in in vitro models of infection that 
reproduce the phammcokinetic profile of the agents in humans. 
The purpose of this thesis was threefold. In the first part an in vitro pharmacokinetic 
model was developed and, in Chapter 2, it was compared to an in vivo model. In particular 
the pharmacodynamics of azithromycin and erythromycin were studied in the in vitro 
model as well as in a lethal mouse peritonitis model of Streptococcus pneumonia. All 
dosing regimens used in the mouse model were simulated in the in vitro model that 
reproduced the phannacokinetie profile of these macrolides in mice. The efficacy was 
expressed as changes in CFUlml the in vitro model while in the animal model CFUs in 
peritoneal washing fluid, blood and, survival experiments were taken to represent efficacy. 
The killing efficacy in tenns of changes in CFU was not fully comparable, most likely due 
to differences in growth conditions in vitro versus in vivo. However, in terms of 
pharmacodynamic parameters predicting efficacy of macrolides the models yielded the 
same answers. Therefore, it was concluded that either model is suitable to investigate the 
pharmacodynamic principles underlying the efficacy of these agents. 
In the second part one of the pharmacodynamic parameters of aminoglycosides, the 
postantibiotic effect (p AE), was investigated. In Chapter 3 the current state of our 
knowledge on the PAE of aminoglycosides is reviewed. The differences between the in 
vitro and in vivo determination of the PAE are highlighted. In vivo the PAE determination 
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starts when the serum concentration of the antibiotic declines below the MIC of the test 
strain, while in vitro the P AE measurement starts much more abmptly when the antibiotic 
is suddenly and completely inactivated or removed from the medium. The procedure of 
inactivation of aminoglycosides by washing or by dilution, has several drawbacks such as 
growth inhibition induced by the method itself (washing) and limiting the sensitivity of the 
test (dilution), especially with antibiotics that have a large initial killing effect on the 
inoculum. Using a dilution of 100 to 1000 times to inactivate the antibiotic results in a 
high detection limit (10' tolO' CFU/ml). In Chapter 4 we described a new method for the 
enzymatic inactivation of gentamicin and tobramycin. The method is easy to perfonn and 
gives comparable results to the dilution method, but circumvents problems that are seen 
with the dilution method. In all studies concerning the PAE of aminoglycosides this 
enzymatic inactivation method was used. In Chapter 5 we questioned whether the P AE of 
tobramycin changes during the interval between doses. Since in vitro PAE measurements 
are routinely based on a short exposure of only 1 to 2 hours, it may not reflect the clinical 
situation in humans where the antibiotic concentration slowly declines over time in 
between consecutive doses. During one dose interval of tobramycin, simulating human 
phannacokinetics in vitro, we detemlined the P AE values at four different time points. The 
result showed that the PAE declined during the dose interval and was zero at the time the 
concentration declined below the MIC. These results seemed in contradiction with earlier 
PAE studies in animal models where the PAE is reported to be longer than in vitro. 
However, in rodents the half-lives of aminoglycoside antibiotics are much shorter than in 
humans. In mice the tm is approximately 30 minutes. It was previously concluded from 
such experiments in mice that the PAE was an important parameter because it gave growth 
inhibition persisting beyond the time after which the antibiotic concentration had become 
lower than the MIC. To explain the difference in PAE from our study and those found in 
the animal studies in Chapter 6 the in vivo condition existing in the experimental animal 
was simulated in our in vitro phannacokinetic model. P AEs were again detennined during 
one dose interval oftobramycin, but now with half-lives of the agent kept in a range of 0.5 
to 2.5 hours. The results again showed that the P AE declined during all dosing intervals, 
but at short half-lives did not reach zero. At a half-life of approximately 2.5 hours the PAE 
132 Summaty 
was zero at the end of the dose interval, indicating that there was no P AE present at the 
end of a dosing interval if the tobramycin half-life in humans would be simulated. This 
might explain, in part, the discrepancy between the in vitro and the in vivo PAE data. 
However, if the half-life oftobramycin in humans was in an experimental animal the PAE 
did not disappear, but was rather longer! This paradox can, in part, be explained by the 
difference in methods of determination of the PAE in vivo versus in vitro. Since in vivo 
the PAE includes the time at which the agent is still present at sub-MIC levels, where in 
vitro the PAE is detennined in an environment that is completely free of active antibiotic. 
The longer PAE seen in vivo can thus at least partially be explained as a sub-MIC effect. 
Another explanation could be that the in vivo PAE values are detennined under different 
enviromnental growth circumstances where host-defenses can also influence growth. 
Based on these observation we concluded that the detennination of PAE of 
aminoglycosides in vitro is not useful and that the true P AE may not exist in humans given 
aminoglycosides for serious bacterial infections. 
In the third part of this thesis the phannacodynamics of combination therapy of 
antimicrobial agents are investigated. In Chapter 7 the laboratory tests used for predictions 
of the effect combination therapy are reviewed. During the last four decades combination 
therapy has been frequently used. Much research efforts have been focussed on all types of 
combinations of antibiotics, but none of these studies have been successful in describing 
the pharmacodynamic principle of combined exposure to two antimicrobial agents. Tltis 
problem was the base for two studies on combination therapy. At first the influence of the 
order of administration of antibiotics during eombination therapy was studied. In Chapter 
8 the combination of tobramycin and ceftazidime against a resistant strain of 
Pseudomonas ael'ugillosa was investigated. The effect of changing the order of 
administration of tobramycin and ceftazidime was studied during a thrice-daily regimen 
for both antibiotics. Since once daily dosing of tobramycin is now commonly excepted, 
this regimen was also investigated in combination with thrice daily ceftazidime. All 
regimens showed a pronounced killing of tltis resistant strain, but the highest efficacy was 
obtained by tobramycin once daily and given as the initial dose prior to the administration 
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of ceftazidime. All regimens showed the combination therapy to have a synergistic effect. 
The major pharmacodynamic parameters used for single agents (monotherapy) are time 
above the MIC (T>,,,c), area under the time concentration curve (AUC) and peak 
concentration (CMAX)' We attempted to develop similar pharmacodynamic parameters for 
combination therapy. In Chapter 9 four resistant strains of Pseudomonas aeruginosa were 
exposed to combination therapy consisting of tobramycin and ceftazidime given in 14 
different regimens. To be able to compare the effect of the concentrations of both drugs at 
a given time point the concentration of each drug was divided by the MIC for that 
respective drug, in a manor that resembles the way a fractional inhibitory concentration 
(FIC) is determined in checkerboard titrations. However, in doing tltis we did not use the 
MICs as they are routinely detennined for a single drug. Because the susceptibility of a 
strain to a given drug may change due to synergistic or antagonistic effects of the presence 
of the second drug. The susceptibility of a strain during combination therapy was 
determined using an E-test for combination therapy, which resulted in a MIC for the two 
agents together (MICco,mJ. The drug concentration at each time-point was divided by this 
MICco,m.; this resulted in the fractional inhibitory concentrations (FICs) at that time-point. 
By adding the FICs for both drugs at each time-point a FICco'IB' versus time curve could 
be constructed. From this curve three new phannacodynamic parameters for combination 
therapy were calculated, i.e. the area under the FICco~mI versus time curve (AUCco~mI)' the 
peak concentration of the FICcOMBI curve (C~iAX_cm.mJ, the time above the Fractional 
Inhibitory Concentration index (T>FlCi)' Using the MICCOMB1 a fourth parameter was 
calculated from the concentration versus time curve of both drugs i.e. the time during 
which at least one of the antibiotic concentrations was above the MICcOMB' (T>MIC.COMBJ. 
The correlation between all four parameters and the therapeutic efficacy was subsequently 
investigated, which showed that in this case the T>FICi had the best predictive value. We 
conclude that in this fashion phannacodynamic parameters can be developed which may 
be used in the future to predict the therapeutic efficacy of combining antimicrobial agents. 
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DIRECTIONS FOR FUTURE RESEARCH 
The studies described in this thesis show that in vitro pharmacokinetic models can be used 
to investigate the antimicrobial effects of all types of dosing regimens and antibiotics. Our 
model can be used to detennine the phannacodynamic properties of new antibiotics, 
without the need for experiments in animals. Especially during development of antibiotics, 
it may be useful to determine these parameters in this model and thereafter validating the 
dosing regimens proposed on the basis of in vitro modeling during phase 1 and phase 2 
studies in volunteers and patients. 
As a follow-up of the work described in this thesis with aminoglycosides it seems 
worthwhile to investigate the P AE of antibiotics which have long in vitro PAEs, including 
the carbapenems (e.g. meropenem) or the newer streptogramines (e.g. synercid). These 
antibiotics show PARs in vitro that may exceed the dose interval, and the in vitro PAE 
may therefore have clinical relevance. The molecular mechanism underlying the PAE 
itself also needs closer examination, if we want fully to understand what causes the PAE. 
For this more work is needed, which ideally should combine the further development of 
the P AE measurements in in vitro pharmacokinetic models and experiments tracing 
transcription and translation of DNA and RNA as was recently done by Gottfredsson et al. 
A most important issue that needs further attention is the investigation of the development 
of pharmacodynamic parameters that could explain andlor predict the efficacy of 
combination therapy. In the last Chapter we have proposed one way that led to 
development of susceptibility tests for combination therapy that can be applied in the 
routine laboratory. This paper describes only one combination of drugs. In the future more 
combinations of drugs, for example quinolones with p-Iactams, should be investigated for 
their pharmacodynamic parameters. Furthennore, there remains a need to repeat the 
experiments with he two agents performed in animal models. The mouse thigh model of 
Craig et al. would be a good starting point, because in this model it is easy to determine 
the killing efficacy of the combination therapy. If these studies yield in the same 
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phammcodynamic parameters as the in vitro modeJ, other animal model may be used for 
further test and survival experiments. However, the many papers, which have been 
published on in vivo synergism indicate that perhaps these data are already available, but 
need to be analyzed again. In this manner our understanding of pharmacodynamics of 
combination therapy may increase and ultimately provide us with tools to predict efficacy 
of combination therapy. 
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SAl\IENVATIING 
De laatste jaren is het belang van de pharmacodynamiek van de verschillende 
antimicrobi~le middelen steeds duidelijker geworden. Bijvoorbeeld weten we hierdoor nu 
dat de effectiviteit van fl-Iactam antibiotica voomamelijk afhankelijk is van de tijd dat de 
concentratie op de plaats van de infektie boven de MIC is, terwiji de effectiviteit van 
aminoglycosiden en quinolonen met name voorspeld wordt door de oppervlaktc onder de 
tijd-concentratie curve (AUC). Gebaseerd op deze kennis werden bestaande 
doseringsschema's aangepast. De pharmacodynamische parameters van anti-microbiele 
middelcn kunnen bestudeerd worden in dier modellen en in in vitro phannacokinetische 
modellen, die het pharmacokinetische verloop van deze middelen in de mens kunnen 
nahootsen. 
Het doel van dit proefschrift was drieledig. In het eerstc deel werd cen in vitro 
phannacokinetische model ontwikkeld wat in hoofdstuk 2 werd vergeleken met een 
diermodel. In deze studie werd de pharmacodynamiek van azithromycine en 
erythromycine bestudeerd in het in vitro model en in een lethaal muis peritonitis model 
met Streptococcus pneumonia. AIle pharmacokinetische doseringsschema's die getest 
waren in het muis model werden gesimuleerd in het in vitro model, waarin het 
pharmacokinetische verloop van deze macroliden in muizen werd nagebootst. De 
effectiviteit van de doseringsschema's werd weergegeven als veranderingen in CPU/ml in 
het in vitro model en in het dier model in CFU's in serum en in peritoneale spoelvloeistof 
en als overlevings curve's. De killing uitgedrukt in CFU was niet volledig vergelijkbaar, 
waarschijnlijk door de verschillende groei omstandigheden in vitro en in vivo, maar voor 
wat betreft de voorspellende waarde van phannacodynamische parameters veer 
effectiviteit waren de beide modellen goed vergelijkbaar en resulteerden in dezelfde 
antwoorden. Daarom werd geconcludeerd dat beide medellen gebruikt kunnen worden om 
de pharrnacody-namische principes en de daaruitvolgende effcctivitcit van de middelen te 
onderzoeken. 
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In het tweede deel werd Un van de pharrnacokinetische parameters, het postantibiotisch 
effect (PAE), van aminoglycosiden onderzocht. In hoofdstuk 3 wordt een overzicht 
gegeven van de huidige kennis over het PAE van aminoglycosiden. De meting van het in 
vivo PAE begint als de antibiotica concentratie in serum daalt beneden de MIC van de test 
starn, terwijl in vitro de meting veel abrupter start als het antibioticum in het medium 
plotseling volledig is geYnactiveerd of venvijderd. De inactivatie van een aminoglycoside 
in bouillon door de wasmethode of via verdunning heeft verschillende problemen zoals 
groei remming door de inactivatie methode zelf (tijdens wassen) en de beperking van de 
detectie grens van de test (verdunningsmethode), vooral bij antibiotica met een groot 
initieel killing effect. Een verdunning van 100 tot 1000 keer om de antibiotica te 
inactiveren resulteert in een hoge detectie grens (102_103 CFUlml). In hoofdstuk 4 wordt 
een nieuwe methode beschreven om gentamicine en tobramycine enzymatisch te 
inactiveren. De methode is simpel uitvoerbaar en geeft vergelijkbare resultaten met de 
verdunningsmethode, maar voorkomt de problemen die de verdunningsmethode laat zien. 
In aile studies die in dit proefschrift over het PAE van aminoglycosiden worden 
beschreven is de enzymatische methode als inactivatie methode gebruikt. In hoofdstuk 5 
werd de vraag gesteld ofhet PAE van tobranlycine verandert tijdens eon doseringsinterval. 
Omdat de in vitro PAE bepaling gebascerd is op een kortdurcnde blootstelling van I tot 2 
UUf, hoeft dit niet overeen te komen met de klinische situatie aangezien in patWnten de 
bacteriepopulatie wordt blootgesteld aan een antibioticum concentratie die afneemt tijdens 
het doseringsinterval. Tijdens een doseringsinterval van tobramycine waarbij de humane 
pharrnacokinetiek werd gesimuleerd in het in vitro pharrnacokinetisch model, werd de 
P AE gemeten op vier verschillende tijdstippen. De resultaten lieten zien dat het PAE 
afnam tijdens een doseringsinterval en nul werd als de antibioticum concentratie onder de 
MIC daalde. Deze resultaten leken in tegenspraak met de eerder door anderen 
gepubliceerde P AE studies in diermodellen, waar het P AE langer bleek te zijn dan in vitro. 
In knaagdieren is de halfwaarde tijd van de antibiotica korter dan in de mens. In muizen 
bedraagt de halfwaarde tijd ongeveer 30 minuten. Het werd al eerder geconcludeerd dat de 
P AE een belangrijke parameter was, omdat het een peri ode van groeiremming beschrijft 
als de antibioticum concentratie al onder de MIC gedaald is. Om het verschil te verklaren 
tussen de PAEs gemeten in ons in vitro model en de in vivo data werd in hoofdstuk 6 de 
diennodel situatie gesimuleerd in het in vitro model. P AE waarden werden gemeten 
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tijdens een doseringsinterval van tobramycine, aileen' nu bij cen halfwaarde tijd die 
varieerde van 0.5 tot 2.5 uur. De resultaten lieten opnieuw zien dat de P AE afnam tijdens 
een doseringsinterval, maar bij korte halfwaarde tijden werd het PAE geen nul. Pas bij een 
balfwaarde tijd van ongeveer 2.5 uur werd het PAE aan het eind van het doseringsinterval 
nul, wat aangeeft dat er aan het eind van cen doseringsinterval tijdcllS de simulatie van de 
situatie in de mens geen PAE meer is. Dit kan voor cen deel het verschil tussen het in vitro 
en in vivo PAE verklaren. Eehter, als in vivo de halfwaarde tijden zoals bij mensen 
worden gesimuleerd, verdwijnt het PAE niet, in tegendeel het verlengt zelfs. Deze paradox 
kan worden verklaard door het verschil in meetmethode van de in vitro en in vivo PAE. 
Omdat de PAE meting in vivo al begint zodra de antibioticum concentratie beneden de 
MIC gedaald is, terwijl in vitro de PAE wordt bepaald in een volledig antibioticum vrije 
omgeving. De tangere in vivo PAE waarde kan dus terullinste vocr cen deel verklaard 
worden als een sub-M1C effect. Een andere verklaring kan zijn dat de PAE in vivo wordt 
gemetcn onder andere omgevingsomstandigheden, die de groeisnelheden kunnen 
belnvloeden. Gebaseerd op deze resultaten is geconcludeerd dat het ill vitro PAE van 
aminoglycosiden niet nuttig is en dat bet echte P AE waarschijnlijk in de mens niet bestaat 
als aminoglycosiden gegeven worden voor ernstige infekties. 
In het derde deel van dit proefschrift wordt de pharmacodynamiek van combinatie therapie 
van antibiotica bestudeerd. In hoofdstuk 7 wordt een overzicht beschreven van de 
laboratorium tests die gebruikt worden om het effect van combinatie therapie te 
voorspellen c.q. beschrijven. Gedurende de afgelopen vier decennia is combinatie therapie 
vaak gebruikt. Veel onderzoek is gedaan naar allerlei antibiotica combinaties, maar geen 
van deze studies kon een pharmacodynamisch principe vaststellen die het effect van 
combinatie therapie kon beschrijven. Dit probleem was de basis voor twee studies over 
combinatietherapie. Als eerste werd de invloed van de doseringsvolgorde van de 
antibiotica op bet killend effect van combinatie therapie onderzocht. In hoofdstnk 8 is de 
combinatie therapie van tobramycine en ceftazidime tegen een resistente Pseudomonas 
aeruginosa onderzocht. Het effekt van de antibiotica doseringsvolgorde van tobramycine 
en ceftazidime werd onderzocht tijdens drie maal daagse doseringsschema's. Omdat de 
eenmaal daagse doseringsvorm van aminoglycosiden steeds vaker gebruikt wordt, werd 
ook deze doseringsvorm onderzocht in combinatie met drie maal daags ceftazidime. Aile 
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doseringsschema's vertoonden een goede killing van deze resistente stam, maar de beste 
effectiviteit werd gezien bij eenmaal daags tobramycine als eerste gevolgd door drie maal 
daags ceftazidime. Aile doseringsschema's vertoonden een synergistisch effect. Tijdens 
therapie met een antibioticum (monotherapie) worden de volgende pharmacodynamische 
parameters gebruikt am het effect te voorspellen: tijd boven de MIC (LMIC), oppervlakte 
onder de tijd versus concentratie curve (AVC) en de top concentratie (CMAX). We hebben 
getracht om vergelijkbare parameters voor combinatie therapie te ontwikkelen. In 
hoofdstuk 9 werden vier resistente Pseudomonas aerugillosa stammen blootgesteld aan 
een combinatie van tobranlycine en ceftazidime tijdcns een veertiental verschillende 
doseringsschema's. Om het effect van de concentratie van beide antibiotica op elk tijdstip 
vergelijkbaar te maken, werden de concentraties van de antibiotica gedeeld door de MIC 
van dat middel, vergelijkbaar met de manier waarop Fractionele Inhiberende 
Concentraties (FIC) worden berekend tijdens schaakbord titraties. Echter, hierbij werd niet 
de MIC gebruikt die routinematig wordt bepaald voor monotherapie. Omdat de 
gevoeligheid van een starn voor een bepaald middel kan veranderen als gevolg van 
synergistische of antagonistische effecten. Daarom werd de gevoeligheid gedurende 
combinatietherapie bepaald m.b.v. een E·test voor combinatie therapic, wat rcslliteerde in 
de MIC voor beide middelen samen (MICCOMBI). Als de antibioticum concentratie op elk 
tijdstip wordt gedeeld door de MICcoMBI resu!teert dit in FICs op dat tijdstip. Door FICs 
van beide antibiotica op elk tijdstip bij elkaar op te tellen kan een FICcOMBI versus tijd 
curve worden geconstrueerd. Met behulp van deze curve kunnen drie ruellwe 
phannacedynamische parameters worden berekend, n.l. de oppervlakte onder de FICcm.1B1 
curve (AVCCOMBI), de top concentratie van de FICCOMBI curve (CMAX.COMBI), en de tijd 
boven de Fractionele Inhiberende Concentratie index (T>FIC'). M.B.V. de MICCOMBI van 
beide antibiotica ken nog een vierde pharmacodynamische parameter worden berekend, 
n.1. de tijd dat temninste <en van de antibiotic a een concentratie had boven de MICcoMBI 
(T>MIC-COMBI). De correlatie van aIle vier de parameters en de therapeutische effectiviteit 
werd onderzocht. Hieruit bleek de T>FIC' de best voorspellende waarde te hebben voor het 
therapeutisch effect. Wij concluderen dat in navolging van deze methode 
pharmacodynamische parameters ontwikkeld kunnen worden, die in de toekomst mogelijk 
gebruikt kumlen gaan worden am het effect van combinatie therapie te voorspellen. 
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AANBEVELlNGEN VOOR TOEKOi\lSTIG ONDERZOEK 
De studies die in dit proefschrift beschreven worden laten zien dat in vitro 
pharmacokinetische modellen gebruikt kUlmen worden om allerlei antibiotica 
doseringsschema's te onderzoeken. Ons model kan worden gebnlikt om 
pharmacodynamische eigenschappen van nieuwe antibiotica vast te stell en, zander dat 
hiervoor dierproeven nodig zijn. Voaral tijdens de ontwikkeling van nieuwe antibiotica 
kan het van belang zijn om deze parameters vast te stellen in het model, om daama de 
volgens het model voorgestelde best mogelijke doseringsschema's te valideren tijdens fase 
I en II studies in vrijwilligers en patienten. 
In navolging van het werk wat in dit proefschrift beschreven wordt, lijkt het zinvol om het 
P AE te onderzoeken tijdens eell doserillgsinterval met een antibioticum wat een lang in 
vitro PAE Iaat zien, zoals de carbapenems (meropenem) of de nieuwere streptogramines 
(synercid). Deze antibiotica vertonen PAE's in vitro die het doseringsinterval 
overschrijden, waardoor ze mogelijk wei klinisch van belang zijn. De moleculaire basis 
die aan het P AE ten grondslag ligt behoeft oak verder onderzoek als we volledig willen 
begrijpen wat het P AE veroorzaakt. Hiervoor is meer onderzoek nodig wat ideaal gezien 
een combinatie ZOU llloeten zijn tussen P AE studies in cen in vitro model en experimenten 
die de transcriptie en translatie van DNA en RNA tijdens de PAE periode bestuderen, 
zoals recent ook door Gottfredsson et al. is gedaan. 
Het meest belangrijke onderdeel dat nog verdere aandacht behoeft, is het onderzoek naar 
phannacodynamische parameters die het effect van combinatie therapie kunnen 
voorspellen en/of verklaren. In het laatste hoofdstuk wordt een methode voorgesteld die 
kan leiden tot de ontwikkeling van een gevoeligheidstest voor combinatie therapie die in 
routine laboratoria gebmikt kan worden. Dit artikel beschrijft slechts cen combinatie van 
antibiotica. In de toekomst zouden voor meer combinaties van antibiotica de 
pharmacodynamische parameters moeten worden onderzocht, zoals bijvoorbeeld 
quinolonen met J3-lactams. Tevens is het nodig om de combinatie therapie schema's die in 
het in vitro model zijn uitgevoerd te herhalen in een diermodel. Het muis-dijbeen 
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spiermodel van Craig et al. zou hiervoor een goed begin model zijll, omdat in dit model 
het goed lUogelijk is om het killend effect van combinatie therapie vast te stellen. Als een 
dergelijke studie dezelfde voorspellende phamlacodynamische parameters voor 
combinatie therapie aantoont, kunnen andere diermodellen worden gebruikt voor verder 
onderzoek naar bijvoorbeeld overlevingsexperimentell. Echter de vele pUblikaties over 
synergisme van combinatie therapie in vivo geven aan dat veel van deze data eigenlijk al 
beschikbaar zijn, maar ze moeten aileen nog volgens nieuwe inzichten geanalyseerd 
worden. Dit zou dan het begrip van de phannacodynamiek van combinatietherapie 
vergroten en ons uiteindelijk middelen opleveren om hCfeffect van combinatie thcrapie te 
kunnen voorspellen. 
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